

# Index

- A
- $\alpha$ -1A AR, 245
- A3 arterioles, 133
- ABC-A1<sup>-/-</sup> mice, 379
- Abdominal aortic coarctation, 238
- Abdominal palpation, 19
- Aberrant renin-producing cells, 372
- Abnormal agitation, 34
- Abnormal feeding behaviors, 24
- Absolute refractory period, 109
- Accelerator, 359
- Accumulation of macrophages, 367
- ACE inhibitor, 183
- Acepromazine, 29, 31, 33, 36
- Acepromazine + buprenorphine, 35
- Acepromazine + buprenorphine + etomidate, 35
- Acepromazine + butorphanol, 31, 33
- Acepromazine + etorphine, 180
- Acepromazine + meperidine, 179
- Acepromazine + oxymorphone, 31, 33
- Acepromazine + pethidine (Meperidine), 31
- Acetaldehyde, 292
- Acetaminophen, 26, 34, 183
- Acetaminophen (Tylenol pediatric suspension), 26
- Acetylcholine (ACh), 261, 338
- Acetylpromazine (Acepromazine), 23, 162–163
- Acid-base balance, 39
- Acidosis, 139
- ACTH-induced hypertension, 280, 281
- Actin cytoskeleton, 244
- Actin-myosin bonds, 86
- Actin polymerization, 289
- Action potential
  - amplitude, 164
  - duration, 139, 170
  - parameters, 158
- Activated allogenic CD8<sup>+</sup> T cells, 127
- Activated ATR-1A receptor, 283
- Activated partial thromboplastin time (aPPT), 6
- Acuson c256, 77
- Acute pain, 17
- Acute recurrent pain, 17
- Acute rejection phenomenon, 127
- Acyl CoA:cholesterol acyltransferase-1 and-2, 317
- Acyl CoA synthase gene, 245
- Acyl-coenzymeA:cholesterol O-acyltransferase-2 (ACAT2), 321
- Adaptive bioenergetic response, 356
- Adaptive changes, 342
- Adaptive identification procedure, 100
- Adenosine, 149
  - receptors, 359
  - uptake, 155
- $\alpha$ -1 Adenosine receptor antagonist, 168
- Adenovirus, 355
- Adenovirus-mediated gene transfer, 373
- Adhesion molecule expression, 210
- Adipocyte fatty acid binding protein promoter (PTG-TG), 362
- Adipocyte hypertrophy, 361
- Adipocytokine, 310
- Adipokines, 361
- Adiponectin (APN), 310
  - antisense transgenic mice, 361
  - knockout (APN<sup>-/-</sup>), 288
  - models, 288
- Adipose fatty acid-binding protein knockout (A-FABP<sup>-/-</sup>) mice, 362
- Adrenal chromaffin cells, 286
- Adrenal steroidogenesis, 152
- Adrenal steroids, 231
- $\beta_2$ -Adrenergic, 160
- $\alpha$ -Adrenergic antagonist, 160
- Adrenergic neurons, 286
- $\beta_1$ -Adrenergic receptor, 271
- $\beta_2$ -Adrenergic receptor, 245

- $\alpha$ -2-Adrenergic receptor agonists, 156–158  
 $\beta$ -Adrenergic receptor function, 236  
 $\alpha$ 2-Adrenergic receptor knockout ( $\alpha$ 2-AR<sup>-/-</sup>) mice, 360  
 $\beta$ -Adrenergic receptor-mediated vasodilation, 264  
 Adrenergic receptors, 359  
 $\beta$ -Adrenergic stimulation, 370  
 Adrenergic terminals, 164  
 $\alpha$ -2-Adrenoceptor, 152  
 $\alpha$ -2-Adrenoceptor agonists, 156  
 Adrenocorticotrophic hormone, 148  
 Adrenomedullin-2 (ADM-2), 339  
 Adrenomedullin-1 (ADM-1) receptor complex, 338  
 Adriamycin, 187  
 Adult metabolism, 4  
 Adult pygmy sperm whales (*Kogia breviceps*), 235  
 Aerobic myocardium, 124  
 Aerobic perfusion, 220  
 Aflaxan (steroid anesthetic agent), 31  
 African green monkeys, 311  
 Afterload, 66  
 Aggression, 24  
 Aging, 87, 94  
 Agitated state, 37  
 Agonist-bound GPCRs, 264  
 Agouti coat color, 204, 205  
 AHR<sup>-/-</sup>mouse, 288, 375  
 Air jet stimulation stress, 342  
 Air jet stress in rats, 268, 341  
 Alanine aminotransaminase (ALT), 7  
 Alanine aminotransferase (ALT), 2, 3  
 Albino rats, 279  
 Albinos, 24  
 Albumin (ALB), 3, 7, 123  
 Albuminuria, 381  
 Alcuronium, 185  
 Aldose reductase, 369  
 Aldosterone, 234, 261, 379  
     activating protein-1, 268  
     synthase mRNA expression, 290  
 Aldosterone synthase (AS), 379  
 Alfentanil, 149  
 Aliskiren, 290  
 Alkaline phosphatase (ALP), 2, 3, 7  
 Alkyphenol intravenous sedative-hypnotic agent, 132  
 Allele of the SA gene, 266  
 Allograft  
     rejection, 363  
     vasculopathy, 363  
 All-or-none law of the heart, 109  
 Alloxan, 311  
 Alpha-agonists, 30, 35–38  
 AlphaB-crystallin, 245  
 Alpha-2-delta, 342  
 Alpha-hydroxybutyrate dehydrogenase, 165  
 Alpha-tropomyosin, 231  
 Althesin, 134  
 Alveolar-arterial pO<sub>2</sub>, 175  
 Alveolar dead space, 156  
 Ameroid casein material, 223  
 Ameroid constrictors, 223  
 Amiloride, 366  
 Aminoglycoside(s), 187  
 Aminosteroid drugs, 185  
 Amisulpride, 170  
 Amitriptyline, 167  
 Amlodipine, 280  
 Ammonium vanadate, 159  
 A-mode (Amplitude) echogram, 71  
 Amphibian brain, 340  
 Amygdala, 332, 340, 346  
 Analgesics, 17  
 Andermann syndrome, 379  
 $\alpha$ -Andrenergic blocking agents, 22  
 $\alpha$ -Andrenergic receptor-mediated vasoconstriction, 264  
 Androgen receptor, 343  
 Androgens, 343  
 Anesthesia, 17–47  
 Angiectasis, 205  
 Angiogenesis, 206  
 Angio-II-induced L-type Ca<sup>2+</sup> currents, 343  
 Angio-II overexpression models, 284  
 Angio-II subtype 1A and 1B receptors (ATR-1A & ATR-1B), 263  
 Angio-I-receptor (ATR-1), 282  
 Angiotensin converting enzyme (ACE) inhibitors, 183, 210  
 Angiotensin-converting enzyme-2 mRNA expression, 275  
 Angiotensin-I converting enzyme (ACE), 267  
 Angiotensin II, 162  
 Angiotensin-II-induced hypertension, 273–276  
 Angiotensin-II infusion, 260  
 Angiotensin II type 1 receptor blockade, 225  
 Angiotensin-II-type 1-(AT-1) receptor density, 261  
 Angiotensin-II-type-2 (ACE-2) receptors, 275  
 Angiotensinogen mRNA expression, 339  
 Angiotensin Pi receptor antagonists, 210  
 Angiotensin-receptor, 344  
     antagonism, 134  
     blockade, 134

- Angiotensin receptor-1 (ATR-1) models, 283–284  
 Angiotensin type II receptors (AT2), 243  
 Angiotensin type-1 receptors (ATR-1), 335  
 Angle of the diagonal motion transducer geometry, 73  
 Anhydrotic effect, 22  
 Animal selection, 1–8  
 Anisotropic viscoelastic properties, 96  
 Anisotropy, 66  
 Anorexia, 365  
 ANP<sup>-/-</sup> mice, 375  
 Anterior and posterior hypothalamic areas, 342  
 Anterior hypothalamic area (AHA), 332  
 Anthracycline  
   antibiotics, 187  
   derivatives, 167  
 Anthracycline-induced cardiomyopathy, 237–238  
 Antiangiogenic properties, 267  
 Anticonvulsants, 21  
 Anti-diabetic actions, 346  
 Antigen expression, 364  
 Antihistamines, 167  
 Anti-hypertrophic pathway, 366  
 Antinociceptive, 341  
 Antinociceptive synergy, 28  
 Anti-ouabain antibody, 278, 345  
 $\alpha$ -2-Antiplasmin ( $\alpha$ -2-AP), 376  
 Antipredatory unconditioned and conditioned behavioral responses, 341  
 Antipsychotics, 167  
 Antithrombin activity, 233  
 Anti-TNF- $\alpha$  monoclonal antibody, 293  
 Anxiety, 24  
 Anxiety responses, 341  
 Anxiolytic agent, 157  
 Aortic arch banding, 236  
 Aortic baroreceptor de-afferentation, 334  
 Aortic bifurcation, 233  
 Aortic-caval shunts (fistulas), 237  
 Aortic coarctation, 277, 367  
 Aortic constriction, 236, 237  
 Aortic cross-clamp, 219  
 Aortic lumen area, 367  
 Aortic nerve pressor reflex, 133  
 Aortic rings, 154  
 Aortic sinus, 367  
 Aortic stenosis, 102  
 Aortic strain, 105  
*Aotus vociferans* (owl monkey), 235  
 Apelin, 244, 377  
 Apelin<sup>-/-</sup> mice, 377  
 Apical aneurisms, 225  
 Apnea, 29, 152  
 Apocynin, 292  
 ApoE<sup>-/-</sup>:apoA-I<sup>-/-</sup> double knockouts, 319  
 ApoE<sup>-/-</sup>:FXR<sup>-/-</sup> female mice, 320  
 ApoE<sup>-/-</sup>:glutathione peroxidase-1 (GPx1)<sup>-/-</sup> mice, 319  
 ApoE<sup>-/-</sup>:Grb2<sup>+/+</sup> mice, 320  
 ApoE<sup>-/-</sup> knockout, 318  
 ApoE<sup>-/-</sup>:P-selectin<sup>-/-</sup> double knockouts, 319  
 ApoE<sup>-/-</sup>:t-PA<sup>-/-</sup> mice, 321  
 Apoe triple-knockout (Apoe 3KO) mice, 290  
 Apolipoprotein-E (ApoE<sup>-/-</sup>), 367  
 Apolipoprotein E-deficient mouse (ApoE<sup>-/-</sup>), 208, 264  
 Apo-lipoprotein E (Apo-E) knockout mice, 104  
 Apolipoprotein E/LDL receptor double knockout mice, 220  
 Apomorphine-induced stereotypy, 169  
 Apoprotein-poor VLDL fragments, 316  
 Apoptosis-driven death rates, 309  
 Apoptosis-signal-regulated kinase-1 (ASK-1)/caspase, 357  
 Apprehensive facial expression, 37  
 Aquaporin 7 (AQP7)<sup>-/-</sup> knockout mice, 322  
 Area-length method, 77  
 Arg92Gln, 241  
 Arg403Gln  
   mutation, 242  
    $\alpha$ -myosin heavy chain mice, 241–242  
 Arginine, 159  
 Aripiprazole, 167, 171  
 Aromatase knockout mice, 356  
 Arousal-promoting, 342  
 $\alpha$ 2c-AR overexpression, 360  
 Arrhythmia-prone subepicardial border zone, 357  
 Arrhythmias, 94, 365, 372  
 Arrhythmic cardiovascular disease, 203–214  
 Arrhythmic actions of catecholamines, 136  
 Arrhythmogenicity, 186  
 Arrhythmogenic right ventricular cardiomyopathy, 232, 233  
 Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C), 234  
 Arterial blood gases, 122  
 Arterial cardiac baroreflex function, 139  
 Arterial compliance, 94–95  
 Arterial flow, 93  
 Arterial HCO<sub>3</sub><sup>-</sup>, 3  
 Arterial input impedance, 93  
 Arterial pCO<sub>2</sub>, 3, 175  
 Arteriolar vasodilation, 134  
 Arteriolipoidosis SHR, 270  
 Arterio-luminal vessels, 110  
 Arterio-sinusoidal vessels, 110

- Arteriovenous shunt blood flow, 172  
 Articaine, 182  
 Artifactual geometrical deformations, 74  
 Artificial valves, 118  
 Aryl hydrocarbon models, 288–289  
 Aryl hydrocarbon receptor (AHR), 288  
 Aryl hydrocarbon receptor knockout (AHR<sup>-/-</sup>) mice, 375  
 A-scan echogram, 71  
 Aspartate aminotransaminase (AST), 7  
 Aspartic acid, 370  
 Asp175Asn, 241, 246  
 Aspirin, 26, 30, 34, 183  
 Astrogliosis, 278  
 Asymmetric annular dilation of the mitral valve, 207  
 Asymmetric dimethylarginine (ADMA), 206  
 Ataxia, 24  
 Atelectasis, 22, 111  
 Atherogenic diet, 311  
 Atherogenic stimuli, 307  
 Atheromatous plaques, 184  
 Atherosclerosis, 3, 94, 264, 307  
 Atherosclerosis-prone with type 1-diabetes (LDLR<sup>-/-</sup>:GP), 323  
 Atherosclerotic diet, 163  
 Atherosclerotic disease, 307  
 Atherosclerotic lesion area, 367  
 Atherosclerotic-like lesions, 206  
 Atipamezole, 23  
 ATP  
   hydrolysis, 86  
   production, 118  
   synthesis, 356  
 ATP-activated potassium channels, 133  
 ATPases, 373  
 ATP-binding cassette transporter A1 (ABCA1), 317  
 ATP-binding membrane cassette transporter-A1 (ABC-A1), 379  
 Atracurium, 185  
 ATR-1 antisense, 283  
 Atrial arrhythmias, 365  
 Atrial contraction, 86  
 Atrial dilation, 86  
 Atrial fibrillation, 211–213  
 Atrial fibrosis, 212  
 Atrial mechanoreceptors, 337  
 Atrial natriuretic peptide (ANP), 151, 233, 234  
 Atrial natriuretic peptide mRNA, 292  
 Atrial natriuretic peptide-null mice [Nppa<sup>-/-</sup>], 244  
 Atrial septal defect (ASD), 203  
 Atrial strips, 65  
 ATR-1 immunoreactivity, 343  
 Atrioventricular (AV)  
   bundle, 211  
   conduction, 68  
   nodal, 145  
 Atrio-ventricular pressure gradient, 86  
 Atrophic kidneys, 262  
 Atropine effects, 133  
 Atropine sulfate, 21  
 Attention-deficit hyperactivity disorder, 269  
 A type lamin [Lmna<sup>(+/+)</sup>], 243  
 Atypical antipsychotics, 169–172  
 Auricular preparations, 164  
 Autoimmune models of cardiomyopathy, 239  
 Autoimmune myocarditis, 210  
 Autoimmunity, 209  
 Autologous blood, 223  
 Autologous pericardium, 207  
 Automated border detection, 81  
 Autonomic nervous activity, 139  
 Autonomic nervous system, 17, 333–334  
 Autonomic reflexes, 135  
 Autoperfused hindlimb preparations, 145  
 Autoregulation, 138  
 Autoregulatory, 114  
 Autoregulatory coefficient, 138  
 Autosomal dominant, 233  
 Autosomal loci, 266  
 A-V conduction, 136, 137  
 2:1 A-V conduction, 69  
 A-V conduction, properties, 69  
 Average speed of ultrasound in soft tissue, 73  
 A-V nodal artery, 154  
 A-V nodal tissue, 160  
 Awake, pregnant ewes, 144  
 A-Wave peak velocities, 79  
 Axl (a receptor tyrosine kinase) knockout (Axl<sup>-/-</sup>) mice, 358  
 Axl<sup>-/-</sup>, receptor tyrosine kinase knockout mice, 278  
 Axolotl (*Ambystoma mexicanum*), 340  
 Axonal sprouting, 344  
 Axon terminals surface/dendrite face, 344  
 Azaperone, 166  
 Azaperone + metomidate, 180  
 A-ZIP/F1 transgenic mouse, 290
- B**  
 Baboons, 102, 222  
 BACH-1, 368  
 BACH-1/ApoE<sup>-/-</sup> (double knockout) mice, 368  
 Balanced serotonin/dopamine antagonist, 170  
 BALB/c mice, 209

- Balloon injury, 314  
Balloon occlusion of the mid-left anterior descending coronary artery, 211  
Balloon volume, 126  
Banding the ascending aorta, 237  
Barbiturate-induced tachycardia, 131  
Barbiturates, 131–132  
Barium titanate, 71  
Barking, 34  
Baroreceptor-heart rate reflex, 131  
Baroreceptor reflex(s), 134, 332, 333  
*Bartonella henselae*, 208  
*Bartonella* sp., 208  
Basal ganglia complex of the CNS, 160  
Basilar arteries, 165  
B6.C-H2 mice, 363  
B6D2F1 hybrid mice, 240  
Beagle dogs, 156  
Beam forming parameters, 73  
Beam width, 71, 76, 80  
Bed nucleus of the stria terminalis (BST), 332  
Behavior  
    body positioning, 24  
    out of character, 34  
Behavioral responses, 341  
Benzodiazepine derivative, 151  
Benzodiazepines, 150, 153–155  
Beta(2)-AR, 143  
Beta cardiac myosin heavy-chain, 231  
Beta3-containing GABA(A) receptors, 152–153  
Beta-gal expression of the *lacZ* gene, 355–356  
Beta globin, 225  
Beta-less mice, 360  
Beta-thalassemia, 225  
Bicarbonate buffer perfusion solution, 120  
Bilateral carotid artery occlusion, 146  
Binary calsequestrin/P2Xr-purinergic receptor (CSQ/P2X4R) transgenics, 374  
Bioluminescence, 355  
Birth weight, 4  
Bispectral index score (BIS), 20  
Bisquaternary ammonium derivatives, 186  
Biventricular isolated working heart preparation, 117, 118  
Biventricular, retrograde-perfused, working heart preparation, 119  
Blastocysts, 205  
B6.LDLR<sup>-/-</sup> mice, 374  
Blood  
    chemistry, 7, 8  
    coagulation mechanisms, 3  
    electrolytes, 122  
    flow, 65  
    velocity, 95  
    volumes, 3  
Blood pressure, 5, 22  
    quantitative trait loci, 270  
    variability, 139, 267  
Blood urea nitrogen (BUN), 7  
Body surface potential maps, 168  
Body temperature, 24  
Body weight, 4, 24  
Bone marrow derived mesenchymal stem cells, 225  
Bone marrow-derived progenitor cells, 292  
Border zone, 221  
*Borrelia burgdorferi*, 208, 209  
*Borrelia burgdorferi* sensu stricto (B31, JD-1, 910255, and N40), 208  
*Borrelia recurrentis*, 209  
*Borrelia* sp., 208–209  
Bosentan, 280  
Bowditch, 109  
Boxers, 234  
Brachial-ankle PWV, 98  
Bradycardia, 135  
Bradykinin (BK), 127  
Bradykinin B2 receptor, 263  
Bradykinin B2 receptor gene (B2<sup>-/-</sup>), 277  
Bradykinin-2 models, 286  
Bradykinin-2 receptor (BR-2), 367  
Bradykinin-2 receptor knockout (B2R<sup>-/-</sup>) mice, 286, 367  
Brain-derived neurotrophic factor (BDNF), 338  
Brain natriuretic peptide (BNP), 233  
Brake, 359  
Brattleboro diabetes insipidus rats, 269  
Breeding age, 4  
Brightness-modulated lines (B-modes), 72  
BRL-47672, 157  
5-Bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-gal), 323–324  
Bronchial and tracheal secretions, 21  
Bronchodilation, 135  
Brown adipose tissue, 332, 336  
Brown-Norway (BN), 267  
    chromosome, 291  
    rats, 192  
Brugada syndrome, 213  
Bubbler, 113  
Bupivacaine, 153, 182  
Bupivacaine-induced onset of ventricular arrhythmias, 153  
Bupivacaine, 26, 29  
Buprenorphine, 22, 30, 34, 147  
Buprenorphine (Buprenex), 27  
Burst pacing, 212

- Butorphanol, 21, 30, 34, 147  
 Butorphanol (Torbugesic), 27  
 Butyrophenones, 164–166  
 Butyrophenone tranquilizers, 166
- C**
- Ca<sup>2+</sup>  
   ATPase activity, 261  
   binding activity, 160  
   influx, 374  
   transients, 157  
   transport in cardiac myocytes, 131  
 Ca<sup>2+</sup>-binding protein, 372  
 Ca<sup>2+</sup>-channel blocking agent, 166  
 C256 Acuson sequoia, 78  
 Cadmium, 270  
 CAD without diabetes, 105  
 Ca<sup>2+</sup>-handling proteins, 357  
 Calcification, 239  
 Calcitonin gene-related peptide family, 339  
 Calcitonin receptor-like receptor, 338  
 Calcium, 3  
   mobilization assays, 347  
   phosphate particles, 120  
   uptake, 86  
 Calmodulin, 163  
 Calmodulin-dependent protein kinase-II  
   (CaMK-II)-dependent phosphorylation  
   of phospholamban, 364  
 Calponin gene, 275  
 Calrectin, 372  
 Calsequestrin (CSQ), in junctional SR, 371  
 Calstabin-2, 214  
 Calves, 4–8, 55–58  
 Ca<sup>2+</sup>-mediated action potentials, 164  
 CaMKII-dependent process, 373  
 Ca<sup>2+</sup>/MLC kinase, 284  
 cAMP phosphodiesterase (PDE), 316  
 cAMP response element binding protein  
   (CREB), 376  
 cAMP specific phosphodiesterase, 244  
 Cannibalism, 24  
 Capacitance, 68  
 Capsaicin, 28, 337  
 Captopril, 245, 268  
 Caravajal syndrome, 234  
 Carboxylated imidazole derivative, 152  
 Carcinoid neoplasias, 208  
 Cardiac allograft survival, 127  
 Cardiac  $\alpha$ -myosin heavy chain promoter, 363  
 Cardiac angiotensinogen mRNA, 271  
 Cardiac calsequestrin, 160, 167  
 Cardiac cathepsin D, 244  
 Cardiac depressants, 21  
 Cardiac devices, 118  
 Cardiac disease, 32  
 Cardiac dysfunction, 271  
 Cardiac fatty acid  $\beta$ -oxidation, 365  
 Cardiac function, 65–87  
 Cardiac index, 103, 174  
 Cardiac lipotoxicity, 238  
 Cardiac muscle, 65  
 Cardiac myosin, 239  
 Cardiac myosin binding protein C (MYBPC3)  
   gene, 232  
 Cardiac myosin heavy chain, 210  
 $\alpha$ -Cardiac myosin heavy chain gene (MHC  
   403/+), 242  
 Cardiac oscillator, 177  
 Cardiac output, 3, 21, 65  
 Cardiac preservation for transplantation, 119  
 Cardiac progenitor cells, 127  
 Cardiac repolarization, 164  
 Cardiac-specific calsequestrin, 245  
 Cardiac-specific hR120GCryAB, 245  
 Cardiac-specific overexpression of Cre-  
   recombinase, 245  
 Cardiac troponin-I, 87  
 Cardiac troponin-I [cTnI (193His)] mice, 243  
 Cardiac troponin T, 231  
 Cardiac troponin Tnt2, 243  
 Cardiac troponin T (cTnT)-Q92, 231  
 Cardiohemodynamic collapse, 163  
 Cardiomyocyte  
   apoptosis, 157, 209  
   conditional knockout of Mdm4, 244  
   death, 157  
   hypertrophy, 127  
 Cardiomyocyte-specific deletion of  
   stat3, 244  
 Cardiomyopathy, 36, 86, 231–246  
 Cardioplegia solution, 114, 219  
 Cardiopulmonary bypass, 133  
 Cardiopulmonary chemoreceptor-activated  
   vagal reflexes, 333  
 Cardiopulmonary effects, 33  
 Cardiorespiratory and locomotor centers, 331  
 Cardiotoxicity, 133, 167  
 Cardiovascular  
   complications, 105  
   hormones, 344  
   malformations, 183  
   phenotyping, 73  
   responses to stress, 165  
 Cardiovascular effects  
   anesthetics, 131–132  
   pharmaceuticals, 172

- post-operative analgesic agents, 139–156, 183
- sedatives, 132–133, 150
- Carotid
  - chemoreceptor, 133
  - chemoreceptor-induced bradycardia, 334
  - occlusion, 134
  - sinus firing frequency, 153
  - sinus nerve, 133
  - sinus reflexes, 133
- Carprofen, 26, 30, 34, 38, 183
- Carrier frequency, 104
- Caspase, 366
- Catabolic enzyme CYP7B1, 357
- Catalase expression, 366
- Catalepsy, 169
- Catecholamine
  - discharge, 222
  - induced hypertension, 132
  - release, 132
- Catestatin, 286, 371
- Cathepsin L, 244
- Cathepsins, 309
- Cathepsin-S (CTSS), 310
- Catheter tip manometer systems, 70
- Cats, 4, 5, 55–58
- Cattle with cardiomyopathy and woolly hair coat syndrome, 234–235
- Caudal pressor area, 335
- Caudal ventrolateral medulla (cVLM), 331
- Caudal vestibular nucleus (CVN), 332, 343
- Ca<sup>2+</sup> uptake into the sarcoplasmic reticulum, 131
- Cauterizing the pulmonic or aortic valves, 237
- Cavalier King Charles Spaniels (Cavaliers), 205
- Caveolae, 368
- Caveolin-1 (Cav-1), 368
  - expression, 280
  - knockout mice, 242
- Caveolins, 379
- Cav-1<sup>-/-</sup> mice, 368
- C57/B16J mice, 177
- C57BL/6J, 242
- C57BL/6J mice, 272
- C57BL/6 mice, 205, 210, 238
- C57BL/6 mice overexpressing human ORPIL, 322
- C57BL/s female mice, 84
- CC chemokine, 310
- CC chemokine receptor-2 (CCR-2), 274, 381
- CCR-2<sup>-/-</sup>, 381
- CD47, 377
- CD<sup>4+</sup> cytotoxic T lymphocyte-mediated destruction of pancreatic islet cells, 362
- CD2-enhanced green fluorescence protein transgenic mice, 355
- CD ETAR<sup>+/-</sup>/CD ETBR<sup>-/-</sup> double transgenics, 285
- CD ETAR<sup>-/-</sup> (collecting duct-specific endothelin A receptor knockout) mice, 285
- CD ETBR<sup>-/-</sup> (CD endothelin B receptor knockout) mice, 285
- CD4<sup>+</sup> helper T (Th) cells, 362
- CD1 mice, 225
- CD36<sup>-/-</sup> mice, 377
- CD47<sup>-/-</sup> mice, 377
- cDNA encoding, 267
- Celecoxib, 183, 293
- Cell- and tissue-based therapies, 362
- Cell-based therapy, 109
- Cellophane, 264
- %-Cells, 307
- Cell-surface carbohydrate phenotype, 363
- Cell-to-cell interactions, 340
- Central amygdaloid nucleus (CEA), 333
- Central chemoreflexes, 149
- Central dopaminergic receptors, 169
- Central hematocrits, 142
- Central inspiratory drive, 334
- Central inspiratory neuronal activity, 334
- Central intravascular volume, 268
- Central respiratory activity, 151
- Central vagal afferent terminal inputs, 337
- Central venous pressures, 149
- Ceramic gas, 113
- Cercopithecus aethiops*, 209
- Cerebellar cortex, 338
- Cerebral blood flow, 136
- Cerebral ventricle, 145
- Cerebrospinal fluid (CSF), 273, 340
- Cerebrovascular reactivity to CO<sub>2</sub>, 135
- Cerebrovasodilation, 140
- CETP transgenic Dahl-salt-sensitive (Tg25) rat, 317
- cGMP-dependent, 336
- CGRP release, 157
- Chamber stiffness index ( $\beta_w$ ), 68, 86
- Characteristic impedance, 100
- Chattering, 24
- Cheek-pouch preparations, 143
- Chemical restraint (sedation)
  - in cats, 36
  - in dogs, 32–33
  - in guinea pigs, 38
  - in pigs, 41
  - in rhesus monkeys, 45
  - in small ruminants, 43
- Chemical transmission of vagal stimulation, 109

- Chemoattractant, 263  
 Chemokine receptors, 127  
 Chemoreceptor  
   afferent activity, 164  
   discharge rate, 142, 148–149  
   response, 134  
 Chemosensory glomus cells, 339  
 Chemotactic polypeptides, 309  
 CHEOPS (Children's Hospital of Eastern Ontario Pain Scale), 19  
 Chest wall compliance, 141, 146  
 C3H/HeJ mice, 209  
 C3H/HeJ strain, 242  
 Chicks, 340  
 Chimeras, 205  
 Chimeric  $\alpha/\beta$  TM (tropomyosin) protein mouse model, 241  
 Chimeric offspring, 205  
 Chimerism, 127  
 Chinchillas, 174  
*Chlamydia pneumoniae*, 314  
 Chloral hydrate, 22  
 $\alpha$ -Chloralose, 133–134  
 Chloralose-anesthetized cats, 333  
 Chloralose+ urethane, 31  
 $\alpha$ -Chloralose + urethane, 134  
 Chloramphenicol, 187  
 Chloroform, 135  
 ChloroPentR, 22  
 Chlorpromazine, 160  
 Chlorpromazine+ ketamine, 31  
 Chlorpromazine+ propofol, 31  
 Chlorpromazine+ thiopental, 31  
 Cholecystokinin (CCK), 337, 348  
 Cholesterol, 3  
 Cholesterol acyltransferase, 163, 379  
 Cholesterol acyltransferase 1 (ACAT1), 308  
 Cholesterol 7- $\alpha$ -OH, 317  
 Cholesterol efflux, 367, 379  
 Cholesterol ester hydrolase, 163  
 Cholesterol ester transfer protein (CETP), transgenic rats, 312, 317, 379  
 Cholesteryl esters, 311  
 Choline, 163  
 Chondromodulin-I, 206  
 Choroidal blood flow, 136  
 Christian Doppler, 74  
 Chromogenic antithrombin activity, 233  
 Chromogranin A, 371  
   (Chga<sup>-/-</sup>) gene, 371  
   gene in mice (Chga<sup>-/-</sup>), 286  
   nodels, 286  
 Chronically instrumented cats, 137  
 Chronically instrumented fetal lambs, 144  
 Chronically instrumented intact, awake rats, 151  
 Chronically instrumented pregnant ewes, 155  
 Chronic heart failure, 356  
 Chronic hypoxia, 292  
 Chronic hypoxia, models  
   of cardiomyopathy, 240  
 Chronic iron-overload, 239  
 Chronic mitral regurgitation, 206  
 Chronic myocardial ischemia models of cardiomyopathy, 238  
 Chronic pain, 17  
 Chronotropic responses, 155  
 Chronotropy, 366  
 Circadian oscillation, 332  
 Circadian rhythms, 291  
 Circumferential extensibility ( $E_c$ ), 96  
 Circumferential strain, 95  
 Cirrhotic cardiomyopathy, 240  
 Cis-monounsaturated fatty acids, 311  
 Cisterna magna, 142  
 Citalopram, 167, 168  
 Clenbuterol, 157–158  
 Clip-ablation model, 262  
 Clipping of the aortic valves, 237  
 Clock gene *Perl*, 291  
 Clock genes *DBP* and *Bmal1*, 291  
 Clomipramine, 167  
 Clonidine, 157, 360  
 Clotting factor XIII (FXIII), 377  
 Clozapine, 167, 169–170  
 Coarctation, 263  
 Codon 180, 241  
 Cognitive modulation of pain, 17  
 Cohen diabetic rat, 269  
 Coil embolization, 224  
 Coimmunoprecipitation experiments, 293  
 Collagen, 87, 99  
 Collagen I- $\alpha$ -2 chain promoter, 355  
 Collagen I gene, 280  
 Collagen-I gene expression, 355  
 Collagen-III mRNA, 271  
 Collagen turnover, 158  
 Collagen type-I mRNA expressions, 368  
 Collecting duct (CD)-specific ET-1<sup>-/-</sup> (CD ET-1<sup>-/-</sup>) mice, 285  
 Color-coded Doppler, 75  
 Colorectal distension  
   (visceral pain stimulus), 341  
 Color flow imaging, 75  
 Combination of PS and tricuspid valve dysplasia, 204  
 Complement deposition, 368  
 Complete AV block, 211



- Compliance, 66  
Computer-assisted tomography (CAT scan), 82  
Con A-induced acute hepatitis, 365  
Concentric ventricular hypertrophy, 365  
Conductance  
  catheters, 82, 83  
  derived volume measurements, 82–84  
Conduction  
  abnormalities, 232  
  velocity, 164  
Confocal studies, 357  
Congenic models, 290  
Congenic SS-16/Mcwi rats, 241  
Congenital cardiac defects, general information, 203–204  
Congenital CYP27B1 mutations, 380  
Congenital deafness, 211  
Congestive heart failure (CHF), 206  
Connexin-40, 365  
Connexin 43, 290  
Connexin (Cx), 372  
  genes, 213  
  subunits, 213  
Conscious cynomolgus monkeys, 149  
Conscious dogs, 139, 141  
Conscious free-moving guinea pigs, 169  
Conscious previously instrumented rabbits, 146  
Conscious previously instrumented rhesus monkeys, 152  
Contamination, 124  
Context sensitivity, 364  
Continuous rapid atrial pacing, 212  
Continuous rate of infusion (CRI), 35  
Continuous wave Doppler, 75  
Contractile proteins, 241  
Contractility, 65  
Control of cardiovascular responses, 331, 343–344  
Copper-deficient diet, 239  
Copper transporter Menkes ATPase (MNK), 275, 374  
Corin, 287, 374  
Corin<sup>-/-</sup> mice, 374  
Corin models, 287  
Coronary arterioles, 110  
Coronary artery disease (CAD), 105  
Coronary circulation, 3  
Coronary collateral system, 221  
Coronary embolization, 222  
Coronary flow reserve, 139, 209  
Coronary graft vasculopathy, 127  
Coronary ischemia-reperfusion injury, 368  
Coronary ligation, 212  
Coronary ostia, 110  
Coronary sinus, 110  
Coronary sinus pressure, 110  
Coronary supply to the papillary muscles, 221  
Coronary vascular resistance, 139  
Cortical blood flow, 279  
Corticosteroids, 18  
Corticosterone  
  concentration vs. time curve, 24  
  levels, 360  
Corticotropin-releasing factor (CRF), 337  
Cortisol, 133  
Cortisol, T3, T4, 8  
Cor triatriatum sinister (CTS), 204  
Counter shock, 211  
COX-2 mRNA, 372  
Coxsackievirus B-2, 209  
Coxsackievirus B-3 (CVB-3), 209  
*Coxsackievirus sp.*, 209  
*cp/cp* male rat phenotype, 316  
C-reactive protein (CRP), 8, 206  
Cre allele, 244  
Creatine kinase activity, 185  
Creatine kinase isoenzyme MB, 165  
Creatine phosphokinase (CPK), 8  
Creatinine (CR), 3, 7  
Creatinine kinase, 165  
CREB-S133A mice, 376  
Creep, 66  
Cre-loxP-mediated deletion, 244  
Cremaster muscle microcirculation, 181  
Cre-recombinase, 341  
Critical anthropomorphic approach, 19  
CrI:JCR(LA)-*Lepr<sup>cp</sup>*, 241  
CrI:ZUC-*Lepr<sup>cp</sup>*, 241  
Cross-sectional area, 101  
Crowding stress, 268  
Crying, 34, 37  
Cryoprobe, 224  
Crystalloid cardioplegia, 220  
Crystalloid perfusion, 124  
CSRP-2<sup>-/-</sup> mice, 379  
C-terminal BRCT repeats of the tumor suppressor BRCA-1, 368  
*cTnI* (PBL<sup>-/-/cTnI</sup>), 370  
*cTnI* gene mutation Gly203Ser, 245  
Cultured bovine adrenal chromaffin cells, 155  
Cuneiform nucleus (CnF), 331  
Curaspon<sup>®</sup>, 238  
Cx37, 372  
Cx40, 372  
Cx43, 372  
Cx45, 372  
Cx46, 372

Cx50, 372  
 Cx57, 372  
 CXC chemokine receptor-4 (CXCR-4), 292  
 CXC family of chemokines, 310  
 Cx40-containing channels, 372  
 Cx30.2, Cx40, Cx43 and Cx45., 213  
 Cx43 gap junctions, 322  
 Cx40<sup>-/-</sup> mice, 372  
 Cyamemazine, 163  
 Cyclic AMP (cAMP), 155, 185  
 Cyclic guanosine monophosphate (cGMP), 133  
 Cyclooxygenase-1 &-2 (COX-1 & COX-2), 183  
 Cyclooxygenase-2 (COX-2), 272  
 Cyclooxygenase-2 inhibitors, 28  
 Cyclooxygenase pathways, 132, 152  
 Cyclosporine, 210  
 Cyp-1 a-1 ren-2 transgenic rat, 290  
 Cysteine, 159  
 Cysteine and glycine rich protein-2 (CSRP-2), 379  
 Cysteine protease, 310  
 Cytoplasmic granulation, 154  
 Cytosolic glutathione reductase (cyto-GR-GFP), 322

## D

Dahl genetic salt-sensitive rat, 270  
 Dahl/Milan QTL-1, 271  
 Dahl salt-sensitive and insensitive rats, 270–273  
 Dahl salt-sensitive rats, 131–132, 236  
 Dahl SS/Mcwi genetic background, 291  
 Daily food consumption, 4  
 Dalmatian dogs, 211  
 Dapoxetine, 167  
 7-Day old chicks, 163  
 DBA-2 mice, 210  
 Db/db mice, 290  
*db/db* mouse, 317  
 DCM in dogs, 233–234  
 D-dimer, 233  
 Dead time, 73  
 Decamethonium bromide, 185  
 Decay time constant ( $\tau$ ), 86  
 Decerebrate, 145  
   cats, 142  
   dogs, 148  
 Decorrelation, 73  
 Decreased conduction velocity, 160  
 Defects in midline closure, 183  
 Deformability indices of red blood cells, 139  
 Dehydroepiandrosterone (DHEA), 291  
 Deletion mouse models, 317

DeltaGlu160, 241  
 Delta receptor mRNA, 338  
 Delta-sarcoglycan (*delta-sgc*), 244  
 Delta-sarcoglycan (*Sgcd*<sup>-/-</sup>), 244  
 Delta-sgc (<sup>-/-</sup>), 244  
 Dendritic attenuation, 331  
 Dentate gyrus, 268, 278  
 Deoxycorticosterone acetate (DOCA)-induced hypertension, 276–278  
 Deoxycorticosterone acetate (DOCA)-salt model, 260  
 Depolarization isointegral maps, 168  
 Depressed contractile reserve, 127  
 Depression, 18  
 Derivatives of propionic acid, 26  
 Dermorphin, 142  
 Desflurane, 31, 35, 138–139  
 Desipramine, 167  
 Desmedetomidine, 31  
 Desmin, 365  
 Desmoplakin, 234  
 Desquamation, 316  
 Development of the isolated heart preparation, 109–112  
 Dexamethasone, 280, 282  
 Dexmedetomidine, 156  
 Dexmedetomidine + butorphanol, 174  
 Dexmedetomidine + ketamine, 175  
 Dextran, 123  
 Dezocine, 27  
 2-D-Guided M-mode, 77  
 Diabetes, 94  
 Diabetes with CAD, 105  
 Diabetic and lipid-toxic models of cardiomyopathy, 238  
 Diabetic retinopathy, 378  
 Diabetogenic diet, 323  
 Diacylglycerol (DAG), 308  
 Diagnostic ultrasound, 71  
 Diagonal motion, 73  
 Dialyzer, 125  
 Diastasis, 86  
 Diastolic left ventricular function, 177  
 Diastolic phase of the Ca<sup>2+</sup> transient, 165  
 Diastolic pressure-volume relation (DPVR), 86  
 Diastolic ventricular/vascular coupling, 104  
 Diazepam, 23, 29, 36, 154–155  
 Dicarboxylic acid esters, 186  
 Dicer, 244  
 Diclofinac, 183  
 Diestrous, 344  
 Diethyl-ether (Avertin), 22  
 Diet-induced hypercholesterolemia, 265  
 Diet-induced hypertension, 273

- Diet-induced obesity, 225, 238  
 Differential modulation by central inspiratory drive, 334  
 Digitalis intoxication, 167  
 Diglycerides, 161  
 Dihydrostreptomycin, 187  
 Dilated cardiomyopathy (DCM), 204, 231, 358  
 2-D imaging, 75  
 Dimensionless slope factor ( $\alpha$ ), 83, 84  
 Diphenylbutylpiperidine derivative, 169  
 Diphtheritic myocarditis, 209–210  
 Dipyridamole, 184  
*Dirofilaria immitis*, 207  
 Disintegrin, 310  
 Disperser, 113  
 Dissecting aortic aneurysms, 240  
 Dissociative anesthetic agents, 150–152  
 Distal embolism, 103  
 Distance resolution, 72, 80  
 Distensibility, 66, 68, 105  
 Distress identification, 24  
 Distribution of Purkinje fibers, 3  
 Divergence, 80  
 D-L-homocysteic acid, 332  
 D79N  $\alpha 2$ -AR<sup>-/-</sup> mice, 360  
 Doberman Pinschers, 233  
 DOCA pellets, 276  
 DOCA plus added salt (DOCA-salt), 276  
 Dog & Cat models, 312–313  
 Dog *in situ* isolated heart-lung preparation, 110  
 Dogs (Beagles), 4–8, 55–58  
 Dominant-negative ErbB-1 mutant receptor, 244  
 Dominant-negative mutant of natriuretic peptide receptor-B (NPR-B $\Delta$ KC), 242  
 Donor cells, 363  
 Donor-specific tolerance, 127  
 Dopamine, 127, 154, 360  
   antagonists, 160, 170  
   excitatory receptors, 160  
 Dopamine- $\beta$ -hydroxylase (DBH), 346  
 Dopamine-blocking, 166  
 Dopamine-induced apoptosis, 133  
 Dopamine (D2)-receptor knockout (D2R<sup>-/-</sup>) mice, 360  
 Dopaminergic transmission, 171  
 Dopaminomimetic activity, 171  
 Doppler angle, 80  
 Doppler echocardiographic, 77  
 Doppler flow velocity, 74–75  
 Doppler sample volume, 80  
 Doppler spectrum analyzer (DSPW), 79  
 Dorsomedial hypothalamus (DMH), 332  
 Dosulepine, 168  
 Dothiepin hydrochloride, 167  
 Double knockout apoE<sup>-/-</sup> and acyl CoA:cholesterol acyltransferase 2 (ACAT2)<sup>-/-</sup> mice, 319  
 Double knockout apoE<sup>-/-</sup>: pregnancy-associated plasma protein-A (PAPP-A)<sup>-/-</sup> mice, 319  
 Double-mutant mice, 242  
 Double mutants (Lepob/ob: LDLR<sup>-/-</sup>), 318  
 Double replacement strategy, 205  
 Double transgenic mice expressing the human renin and Angio-II genes, 290  
 Double transgenic mice that express the human renin and angiotensin genes (h-Ang 204/1 h REN 9), 290  
 Double-transgenic rats harboring both human renin and human angiotensinogen genes, 366  
 Doxepin, 167  
 Doxorubicin, 187, 237  
 Doxorubicin-induced cardiomyopathy, 237  
 Doxycycline (DOX)-regulated transcriptional activator (rTA), 246  
 $dP/dt_{max}$ , 70, 103  
 Droperidol, 23  
 D-tubocurarine, 185  
 Dual endothelin (ET) receptor inhibition, 294  
 Duchenne muscular dystrophy, 234  
 Duchenne's dilated cardiomyopathy, 234  
 Ducks, 138  
 Ductal constriction, 183  
 Dull attitude, 34, 37  
 $dV/dt_{max}$ , 164  
 Dwarf sperm whales (*Kogia simus*), 235  
 Dynamic response characteristics, 70  
 Dynamic right ventricular obstruction, 204  
 Dysferlin, 244  
 Dyslipidemia, 307  
 Dystrophin, 244
- E**  
 E-4031, 182  
 Ea, 102  
 Ea/Ees, 101  
 Ea/Ees ratios, 102  
 E/A ratios, 77  
 Early after-depolarizations (EADs), 164, 167  
 Ebstein's anomaly of the tricuspid valves, 203  
 Eccentric physiologic ventricular hypertrophy, 355  
 Ecdysone-inducible gene expression, 244  
 ECG, 68  
 ECG-gating, data acquisition, 76, 82

- Echocardiogram-derived indices of contractility, 138
- Echocardiography, 70–74, 81, 206
- Echo technology, physics of, 72–74
- EC-SOD, 275
- Ectonucleoside triphosphate diphosphohydrolase-1 (CD39), 368
- Ectopic automaticity, 155
- Ectopic beats, 154
- Ectopic pacemaker activity, 136
- EDHF activity, 127
- Endothelin type-B receptors (ETBR), 186
- Ees, 67
- Effective alveolar volume, 175
- Effective refractory period, 68, 164
- Ejection fraction(s), 3, 132
- Elasticity imaging, 66, 104–105
- Elastic properties, 65
- Elastic recoil, 77, 86
- Elastin (ELN), 376
- Elastin gene, 376
- Elastography, 85
- Electrical activity, 68
- Electrical alternans, 167
- Electrical field stimulated contractions, 157
- Electrically induced fibrillation, 211
- Electric near field, 69
- Electroconductive balloon, 116
- Electroencephalographic burst suppression pattern, 132
- Electron spin resonance signals, 337
- E<sub>max</sub> (E<sub>max</sub>), ranges of, 56
- Embryonic death, 364
- Embryonic endothelial progenitor cells (eEPCs), 381
- Embryonic stem cells (ESC), 204, 287
- Emergence delirium, 151
- Emotional behavior, 24
- Enalapril, 265
- Enkephalin, 284
- Encephalomyocarditis virus, 210
- End-diastolic pressure-volume relationship (EDPVR), 68
- Endocardial anastomoses, 221
- Endocardial fibrosis, 163
- Endocardial ischemia, 126
- Endocardiosis of the mitral valve, 211
- Endogenous antioxidant thioredoxin (Trx), 357
- Endogenous digitalis-like factor (EDLF), 278
- Endogenous opioid peptides, 276
- Endogenous ouabain-like substance (OLS), 345
- Endogenous peptide system, 377
- Endogenous tetrapeptide N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP), 275
- Endoplasmic reticulum, 308, 337, 372
- End-organ damage, 276
- β-Endorphin, 148
- s-Endorphins, 346
- Endothelial barrier function, 368–369
- Endothelial cell-restricted NF-κB super-repressor IkappaBalphadeltaN (Tie-1-DeltaN) overexpression, 369
- Endothelial Cre transgenic, 294
- Endothelial dysfunction, 277
- Endothelial injury, 223
- Endothelial NOS (eNOS), 271
- Endothelial progenitor cells (EPCs), 359
- Endothelial-specific tie2 promoter, 365
- Endothelin
- antagonist, 220
  - models, 285
- Endothelin-1 (ET-1), 234, 262, 375
- Endothelin-1 precursor, 271
- Endothelin receptor subtype B null (ETBR<sup>-/-</sup>) rats, 272
- Endothelin type-B receptors (ETBR), 286
- Endothelium-dependent component of the potassium ATP<sup>+</sup> channel-induced pulmonary vein vasorelaxation, 132
- Endothelium-dependent relaxations, 127
- Endotoxin-induced pulmonary inflammation, 151
- Endotracheal extubation, 147
- End-systolic pressure-diameter relationship, 67
- Energy
- balance, 346
  - homeostasis, 361
- English Cocker Spaniels, 234
- eNOS downregulation, 286
- eNOS<sup>-/-</sup> mice, 264, 285, 360
- eNOS models, 285
- Ensemble size, 80
- Enteroendocrine cells, 348
- Environmental stressors, 267
- Enzymatic activity of CD39, 368
- Enzyme levels, ranges of, 7
- Epicardial activations times, 136
- Epicardial surface, 69
- Epidural, 144
- Epidural pressures, 136
- Epinephrine response, 171
- Epoxyeicosatrienoic acid (EET)-mediation of flow-induced dilation, 356
- Epstein-Barr virus genome, 363
- Equilibrium studies, 82

- ER- $\alpha$ -immunoreactive cells, 343  
ErbB-2 tyrosine kinase receptor, 244  
ErbB-4 tyrosine kinase receptor, 244  
ER- $\beta^{-/-}$  (BERKO) mice, 356  
ERR- $\alpha$ , 370  
ERR- $\gamma$ , 370  
Erythromycin, 187  
Erythropoietin, 245  
Escitalopram oxalate, 167  
Esmolol, 77  
ESPVR, 67  
Essential hypertension, 259  
Esterification of cholesterol, 163  
Estradiol, 278  
17- $\beta$ -Estradiol, 131, 344  
Estradiol benzoate pellet, 268  
Estrogen  
    deletion, 356  
    models, 287  
    receptor antagonists, 356  
    receptor subtypes ( $\alpha$  and  $\beta$ ), 356  
    replacement, 272  
    treatment, 268  
Estrogen receptor- $\alpha$  knockout (ERKO)  
    mice, 356  
Etanercept, 293  
Ether, 135, 140  
Ether-a-go-go-related gene (ERG),  
    140, 213  
Etodolac, 183  
Etomidate, 152–153, 183  
Etorphine, 27  
E2 ubiquitin-conjugating enzymes, 242  
E3 ubiquitin ligases, 242  
E-wave deceleration times, 78  
E-wave peak velocities, 79  
Excessive licking, 37  
Excessive sleeping, 37  
Excitation-contraction coupling, 131, 371  
Excitatory orexin neuropeptides, 342  
Excitotoxic lesions, 345  
Exerciser, 3  
    endurance, 355  
    training, 331  
Exogenous inotropic agents, 65  
Exon 4, 379  
Expected vocalization, lack of, 34  
Express cardiac troponin-I  
    (PBL/cTnI), 370  
Extra-cardiac stem cells, 127  
Extracellular matrix, 86, 158  
    proteins, 86  
    protein turnover, 272  
Extracellular nucleotides, 368  
Extracellular signal-regulated kinase 1–2  
    (ERK1/2), 273  
Extraglomerular mesangium, 372  
Extra nuclear estrogen receptors (ER), 343
- F**  
Factor VIII coagulant activity, 233  
Fadogia homle, 239  
Familial hypertrophic cardiomyopathy, 231  
Family 78, 242  
Farnesoid X receptor (FXR), 320  
Fas ligand (FasL), 373  
Fast Fourier transform (FFT), 75  
Fasting hyperglycemia, 361  
Fasting hyperinsulinemia, 285, 360  
Fatty acids, 124  
    oxidation genes, 366  
    transport protein CD36, 376  
Fatty Zucker rat, 315  
Fazadinium, 185  
F2 backcrosses, 266  
Fear, 341  
Feces output, 24  
Feline amylase, 3  
Feline total bilirubin, 3  
Femoral artery-vein shunts, 237  
Fenoterol, 158  
Fentanyl, 27, 35, 145–147  
Fentanyl + droperidol (Innovar-Vet®),  
    28, 33, 180  
Fentanyl+ fentanyl, 31  
Fentanyl+ isoflurane or sevoflurane, 31  
Fentanyl + morphine, 180  
Fentanyl patches, 35, 145  
Fentanyl + propofol, 181  
Ferrets, 2  
Ferric reducing ability of the plasma (FRAP),  
    206, 234  
Fetal glucose uptake, 144  
Fetal heart rate, 155  
Fetal O<sub>2</sub> consumption, 144  
Fetal sheep preparations, 149  
Fezolamine, 171  
Fiber shortening, 80  
Fibrinogen, concentrations, 6, 233  
Fibrinoid necrosis, 235  
Fibrous cap, 308  
Fibulin-4 knockout mice, 208  
Finite noise, 73  
Firefly luciferase, 355  
First pass method, 81  
First phase relaxation, 86  
Fischer rats, 176

- Fisher rat, 317  
 F-2-isoprostane, 311  
 Flow-regulated preparations, 114  
 Flow-regulated system, 112  
 Fluid-filled catheter, 69, 70  
 Fluid shear rates, 309  
 Flunixin, 30, 183  
 Flunixin meglumine, 34, 37  
 Flunixin-meglumine (Banamine), 26  
 Fluoroquinolone, 187  
 Fluoxetine, 167  
 Fluvoxamine maleate, 167  
 Foam cells, 308  
 Focal spot distance, 80  
 Follitropin-receptor knockout mice (FORKO),  
     274, 357  
 Food consumption, 4, 24, 347  
 Foot velocity, 98  
 Force  
     displacement measurements, 95–97  
     frequency relation, 139  
     frequency relationship, 139  
     velocity relationship, 65  
 Forskolin-induced reduction of tension, 364  
 Fos-immunoreactivity, 340  
 Fractalkine, 309  
 Fractional area change, 132  
 Fractional shortening, 132  
 Frame rate, 73, 76, 80  
 Frank, O., 109  
 Free fatty acid  
     acid levels, 308  
     concentrations, 151  
 Freezing behavior, 155  
 Frequency  
     of Ca<sup>2+</sup> release, 139  
     response, testing, 70, 126  
     of transducer, 80  
 Frogs, 340  
 Fructosamine, 311  
 Fructose, 272  
 Fructose-overloaded rats, 291  
 Full-length thrombopoietin receptor (Mpl)  
     transgene, 378  
 Functional CSRP-2 (CSRP-2<sup>-/-</sup>), 379  
 Fused binding-domain-activator chimera, 355  
 FVB.LDLR<sup>-/-</sup> mice, 374  
 FVB/N mice, 289  
 FXIII<sup>-/-</sup> and FXIII<sup>+/-</sup> mice, 377  
 FXIII, transglutaminase, 377  
  
**G**  
 GABAergic inputs, 154  
 GABAergic receptors, 335  
 GABA transporter-2, 344  
 β-Galactosidase (β-gal), 363  
 β-Galactosidase-neomycin  
     phosphotransferase (β-geo)  
     cassette, 287  
 Gallamine, 185  
 G-alpha proteins, 245  
 Gamma-aminobutyric acid (GABA), 335, 340,  
     341, 344  
 Gamma camera, 81  
 Gamma or x-rays, 81  
 Ganglionic blockade, 278, 345  
 Gap junctions, 213  
 Gal-4 promoter, 355  
 Gastroduodenal ulcers, 183  
 Gastrointestinal hormone, 348  
 Gated studies, 72  
 Gatifloxacin, 187  
 G (i)-coupled receptor (Ro1), 245  
 Gender differences, 343  
 Gender effects on central control of  
     cardiovascular responses, 343  
 Gender-specific (male) enhanced response  
     to phenylephrine, 357  
 Gene disruption cassette, 379  
 Gene-gene interactions, 321  
 General anesthesia, 39  
 Gene-targeted mice, 345  
 Genetically engineered mice with PGI2  
     deletions, 184  
 Genetic engineering, 363  
 Gene trap integration, 287  
 Genome-wide scanning, 259  
 Gentamicin, 123, 187  
 Geometry of the ventricle, 81  
 German Shepherd dogs, 156, 234  
 GI  
     secretions, 21  
     smooth muscle motility, inhibition of, 21  
     stasis, 21  
     toxicosis, 26  
 Ginsenoside (TG), 293  
 Glass  
     beads, 222  
     microspheres, 102  
 Glial cells, 273, 340  
 Glial fibrillary acidic immuno-positive  
     astrocytes, 268  
 Glibenclamide, 220  
 Global ischemia, 117, 154, 179, 219  
 Glomerular filtration rate (GFR), 33, 183, 279  
 Glomerular sclerosis, 279, 315, 381  
 Glomeruli, 262  
 Glomerulonephritis, 235  
 Glucagon-like peptide-1 (GLP-1), 340

- Glucocorticoid-induced hypertension, 280–281  
 Glucocorticoid receptor (GR), 282, 287  
 Glucose, 3, 6  
   excursions, 362  
   intolerance, 356, 361  
   oxidation, 376  
   utilization, 279  
 Glucose-6-phosphate dehydrogenase, 314  
 Glucose-6-phosphate dehydrogenase (G6PD)  
   mutant mice, 319  
 Glucose transporter-4 knockout (GLUT-4<sup>-/-</sup>)  
   mice, 361  
 Glu180Gly, 246  
 Glu189Gly in  $\alpha$ -tropomyosin, 241  
 Glu54Lys, 242  
 Glutamate, 332, 335, 337, 338, 341–343  
 Glutamate-aspartate-enriched blood  
   cardioplegic solution, 221  
 Glutamate-induced facilitation of the L-type  
   VDCC current, 338  
 Glutamate-induced stimulatory effects, 335  
 Glutamate-N-methyl-D-aspartate (NMDA)  
   receptor, 341  
 Glutamic-oxaloacetic transaminase, 165  
 Glutamine, 220  
 Glutathione peroxidase, 246  
 Glutathione redox status, 292  
 GLUT-4 mRNA, 366  
 Glycation cross-linking, 87  
 Glycoprotein (GP) expressing %cells, 323  
 Glycosylphosphatidylinositol (GPI)-anchored  
   human lipoprotein lipase (LpLGPI), 245  
 Glycyrrhizic acid, 291  
 Gly203Ser cTnI-203 mice, 241  
 Goats (adult), 4–8, 55–58  
 Goldblatt preparation, 259  
 Golden hamsters, 344  
 Golden Retriever muscular dystrophy, 234  
 Golden Syrian hamster, 127, 324  
 Gold thioglycose (GTG), 323  
 Gonadal hormones, 21  
 Gonadal steroid-sensitive behaviors, 341  
 Gonadotropin-releasing hormone  
   neurons, 347  
 Gottingen mini-pigs, 162, 173  
 Gousiekte, 239  
 GPCR kinases (GRKs), 284  
 G6PD hemizygous (E-Hemi), 319  
 Gp39 precursor, 339  
 G protein, 239  
 G protein-activated, inward rectifying K<sup>+</sup>  
   channels (GIRK or Kir3 channels), 167  
 G-protein-coupled ET (A) and ET (B)  
   receptors, 272  
 G-protein-coupled receptor (GPCR) kinase 2  
   (GRK-2), 264, 357  
 G-protein-coupled receptors (GPCRs),  
   284, 359  
 G-protein models, 284–285  
 G(i) proteins, 143  
 G(s) proteins, 143  
 G-protein signaling, 280  
 Graft vasculopathy, 323  
 Granatanol, 186  
 Granulocytic inflammation, 363  
 Green fluorescent protein (GFP), 204, 322  
 Greyhounds, 183  
 GR fusion protein, 287  
 Grooming, Lack of, 37  
 Growling, 34  
 Growth factor gene expression, 309  
 Growth plate phenotype, 380  
 Grunting, 24  
 Gs-adenylyl cyclase activity, 278  
 G subfamily of ATP-binding cassette (ABC)  
   transporters, 367  
 GTP binding protein Rac, 284  
 GTP cyclohydrolase-1 (GTPCH-1), 292  
 Guanethidine, 136  
 Guanylate cyclase, 356  
 Guarding, 18  
 Guinea pigs, 4–8, 55–58, 143  
 Gunn rats (hyperbilirubinemic), 359
- H**  
 Halogenated anesthetic agents, 135  
 Haloperidol, 165–166  
 Halothane, 22, 31, 136–137  
 Hamburger and Hamilton stage 13–14 chick  
   embryos, 140  
 Hanford and Yucatan miniature pigs, 312  
 Harlequin Great Danes, 211  
 Harmonic analysis, 96  
 HCM/GSK-3- $\beta$  double transgenic mice, 358  
 Hcy-thiolactone, 323  
 HDI 5000 SonoCT, 77  
 HDL-cholesterol, 308  
 5-Hydroxytryptamine, 161  
 5-Hydroxytryptamine-1A [5-HT(1A)]  
   receptors, 336  
 Head-up tilt, 162  
 Heart failure, 87, 94, 231–246  
   hypertensive, 86  
 Heart failure with normal ejection fraction  
   (HFnEF), 87  
 Heart glucose transporter-4 (GLUT-4) mRNA  
   expression, 366  
 Heart-lung preparation from cats, 110



- Heart preservation, 109  
 Heart rate, 5, 22, 24, 103, 154  
   variability, 154  
 Heart transplants, 126  
 Heartworms, disease, 1, 207  
 Heat shock-like protein  $\alpha$ B-crystallin  
   (CryAB(R120G)), 245–246  
 Helical carotid artery strips, 163  
 Hematuria, 152  
 Heme oxygenase (HO-1<sup>-/-</sup>), 263, 359  
 Heme oxygenase inducer (hemin), 268  
 Heme oxygenase-1 knockout (HO<sup>-/-</sup>) mice,  
   276, 359  
 Hemi channels, 372  
 Hemochromatosis gene knockout (Hfe<sup>-/-</sup>)  
   mice, 362  
 Hemolysis, 152  
 Henseleit, K., 120  
 Heparin, 122, 275  
 Hepatic artery blood flow, 132  
 Hepatic glucose production, 361  
 Hepatic lipase (HL), 317, 379  
 Hepatic O<sub>2</sub> supply, 132  
 HERG, 168  
 Heritable HCM in cats, 232–233  
 Heterogeneous nuclear ribonucleoprotein  
   K, 271  
 Heterogeneous signaling modalities, 340  
 Heteromeric channel, 372  
 Heterotopic heart, xenografts, 127, 323  
 Heterotopic transplants, 126, 127  
 Heterotrimeric G-proteins, 284  
 Heterozygous bone morphogenetic protein  
   receptor-II-knockout (BMPR-2<sup>+/-</sup>)  
   mice, 294  
 Heterozygous glucocorticoid receptor (GR  
    $\beta$ -geo<sup>+/-</sup>) mice, 287  
 Heterozygous Tnnt2<sup>+/-</sup> mice, 243  
 Hexokinase-I, 338  
 Hexokinase-I mRNA labeling, 338  
 HFnEF (heart failure, normal ejection  
   fractions), 103  
 Hiding, 37  
 HIF-1 $\alpha$  decoy oligodeoxynucleotides  
   (ODNs), 289  
 HIF-1 $\alpha$  protein expression, 143  
 High-altitude (brisket) disease in cattle, 293  
 High cholesterol, 3  
 High density lipoprotein (HDL), 7  
 High fat diet, feeding, 3, 264, 310  
 High-fat diet-induced insulin resistance, 356  
 High fat-high cholesterol diets, 311  
 High-fidelity left ventricular catheter, 177  
 High frequency recordings, 24  
 High-frequency ultrasound biomicroscopy, 73  
 High-pressure mechanoreceptor-activated  
   vagal reflexes (ramp baroreflex), 333  
 High salt diets, 335  
 High sucrose diet, 317  
 Hip dysplasia, 33  
 Hirudin, 110  
 HIS-Purkinje, 137  
 HIS-Purkinje tissue, 160  
 Hissing, 37  
 Histamine, 142  
 Histamine receptor-sensitive pathways, 144  
 Histaminergic, 150  
 Histiocytic myocarditis, 209  
 Hitachi EUB 8000, 77  
 HLA-DQ8 (+) RAG-1<sup>-/-</sup>mII<sup>-/-</sup>-non-obese  
   diabetic mice, 210  
 Homeodomain transcription factor Orthopedia  
   (Otp), 339  
 HO-1<sup>-/-</sup> mice, 359  
 Homocysteine (Hcy), 206, 323  
 Homocysteine-induced abnormalities, 206  
 Homologous recombination, 205, 283  
 Homomeric gap junction, 372  
 Homozygous mutant mice, 205  
 Homozygous null Tnnt2 (<sup>-/-</sup>), 243  
 Homozygous osteopetrotic mice (Op/Op),  
   274, 375  
 Hooded (Aguti) rats, 272  
 Hormone-sensitive lipase, 317  
 Howling, 34  
 5-HT2A antagonist, 170  
 5-HTT-deficient mice (5-HTT<sup>-/-</sup>), 208  
 5-HT transporter (SERT) uptake inhibitor, 168  
 Human  $\alpha$ , 2-fucosyltransferase (HT), 363  
 Human apolipoprotein B (ApoB), 322  
 Human cholesteryl ester transfer protein  
   (CETP), 322  
 Human complement inhibitors, 363  
 Human decay accelerating factor (hDAF), 363  
 Human endothelin-1 cDNA, 246  
 Human ether-a-go-go-related gene (HERG), 161  
 Human familial hyperlipidemia (FH), 320  
 Human HLA-DQ8 molecule, 210  
 Human ICAM-2 promoter, 355  
 Human IL-2 promoter, 363, 365  
 Human limb girdle muscular dystrophy type  
   2F, 244  
 Human metabolic syndrome, 270  
 Human paraoxonase 3 (PON3), 322  
 Human preproET-1 gene, 285, 375  
 Human receptor-interacting serine-threonine  
   kinase-3 (hRIP3), 206  
 Human serum-mediated lysis, 363



- Human TBX-5, 377  
 Hyaline necrosis, 239  
 Hydralazine, 260  
 Hydration, 1–2  
 Hydraulic occluder, 223, 261  
 Hydraulic sinusoidal pressure wave generator, 70  
 Hydrocarbons, 161  
 Hydro mineral homeostasis, 342  
 Hydromorphone, 36  
 Hydromorphone + diazepam, 31  
 Hydromorphone + glycopyrrolate, 36  
 Hydrophone, 85  
 20-Hydroxy-eicosatetraenoic acid (20-HETE), 277, 366  
 11- $\beta$ -Hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2), 347  
 11- $\beta$ -Hydroxysteroid dehydrogenase type-2, 282, 338  
 5-Hydroxytryptamine (5-HT), 159, 163, 166  
 5-Hydroxytryptamine-1A [5-HT(1A)] receptors, 336  
 5-Hydroxytryptamine receptor antagonists, 28  
 Hyperactive but not hypertensive (WKHA), 269  
 Hyperbilirubinemic mutant Gunn rats, 276  
 Hypercapnia, 139  
 Hypercholesterolemia, 264  
 Hypercholesterolemic, 208  
 Hypercholesterolemic apoE<sup>-/-</sup>: LDR<sup>-/-</sup> double knockout mice, 319  
 Hyper-coagulability, 233  
 Hyper contraction, 220  
 Hyperglycemia, 307  
 Hyperinsulinemia, 307  
 Hyperlipidemia, 360  
 Hyperlipidemic diet, 101  
 Hyperpolarization-activated cyclic nucleotide-gated channel-1, 372  
 Hyperpolarization, vascular smooth muscle, 154  
 Hyperpolarizing, 133  
 Hyperpolarizing synaptic drive potentials, 146  
 Hyper reactivity, 24  
 Hyper-reflexia, 18  
 Hypersensitivity reactions, 210  
 Hypertension, 94, 174  
 Hypertension but not hyperactive (WKHT), 269  
 Hypertensive nephropathy, 274  
 Hyperthyroid and hyper-adrenergic models of cardiomyopathy, 240  
 Hypertonicity, 345  
 Hypertonic saline, 83  
 Hypertriglyceridemic, 315  
 Hypertrophic cardiomyopathy (HCM), 211, 231, 358  
 Hypertrophic remodeling, 286  
 Hypertrophic response, 377  
 Hypertrophy, 87, 219  
 Hyperventilation, 37  
 Hypervitaminosis D, 101  
 Hypokinesia, 232  
 Hypomorphic expression allele, 208  
 Hyponatremia, 168  
 Hypophysiotrophic zones, 340  
 Hypothalamic arginine vasopressin mRNA, 268  
 Hypothalamic blood flow, 275  
 Hypothalamic brain slices, 154  
 Hypothalamic diabetes insipidus, 268  
 Hypothalamic neuropeptides, 347  
 Hypothalamic paraventricular nucleus (HPVN), 331, 339–340  
 Hypothalamic-pituitary-adrenal (HPA) axis, 18, 287  
 Hypothalamic-pituitary-adrenal axis responses, 331  
 Hypothalamus, 278  
 Hypothermia, 171  
 Hypoxemia, 138  
 Hypoxia, 103, 339  
 Hypoxia-induced pulmonary hypertension, 292–293  
 Hypoxia inducible factor (HIF)-1 $\alpha$ , 289
- I**
- Iatrogenic cardiac arrhythmias, 211–214  
 Iatrogenic models of ischemic heart disease, 219–225 of valvular disease, 207–208  
 Iatrogenic portal venous constriction, 184  
 Ibuprofen, 26, 34, 183  
 IFN- $\gamma$ -producing cells, 363  
 IGF binding protein-4 (IGFBP-4), 309  
 IgG auto antibodies, 210  
 IL-6, 246  
 IL-1- $\beta$ , 339  
 Ile79Asn, 241  
 IL-4-expression in T helper (Th) cells, 363  
 IL-10 transgenic, 363  
 IL-4 transgenic mice, 363  
 Imipramine, 167  
 Immune-mediated liver injury, 365  
 Immune recognition, 364  
 Immunodeficient, 321  
 Immunological rejection, 363  
 Immuno-protease subunit-7 (LMP-7), 262  
 Immunosuppression, 127  
 Impaired myocyte relaxation, 127  
 Impedance phase angle, 99

- Impulse force, 85
- Impulse response (IR), 100
- Inappropriate urination or defecation, 34, 37
- In awake adult horses, 148
- Incompressibility, 67
- Increasing the ventricular workload, 236
- Indomethacin, 183
- Inducible NO synthase (iNOS), 271
- Infectious cardiovascular disease, 208–209
- Infectious complications following burn injury, 210
- Inferior olivary nucleus (ION), 332
- Infiltrating macrophages, 374
- Inflammatory chemokines, 361
- Inflammatory cytokines, 263, 365
  - pathways, 206
  - responses, 210
- Inflammatory infiltrates, 368
- Inflatable cuff, 223
- Inhalation anesthetic agents, 135–141
- Innovar vet (mixture of fentanyl + droperidol), 33
- iNOS, 143
- Inositol 1,4,5-triphosphate, 268
- Inositol (1,4,5)-trisphosphate-mediated  $\text{Ca}^{2+}$  (INS (1,3,5) P3-dependent  $\text{Ca}^{2+}$  signaling pathway, 143
- Input impedance, 99
- Instantaneous compliance, 100
- Instantaneous impulse-response, 100
- Insular cortex (IC), 331
- Insulin-like growth factor-1 (IGF-1), 206, 309
- Insulinomas, 2
- Insulin receptor knockout (IR<sup>-/-</sup>) mouse, 361
- Insulin receptor substrate-2 (IRS)<sup>-/-</sup> female mice, 318
- Insulin resistance, 270, 307, 362
- Insulin sensitivity, 270
- Insulin-stimulated glucose uptake, 285, 360
- Intact awake animals
  - dogs, 145
  - goats, 181
  - horses, 144, 162, 177
  - pigs, 153, 173
  - rabbits, 149
  - rats, 170
- Intact, awake, previously instrumented animals
  - dogs, 148, 154
  - pigs, 143, 155
  - primates, 147
  - rabbits, 151
  - sheep, 153
- Integration sites, for cardiorespiratory and locomotor responses, 331
- Integrative cardiorespiratory and locomotor site, 333
- Integrative central control, 331
- $\beta$ -1-Integrin knockout ( $\beta$ -1<sup>-/-</sup>) mice, 365
- Intercalated disk, 365
- Intercalated disk protein Xin, 242
- Intercellular adhesion molecule (ICAM)-1 (E-selectin), 308
- Intercellular adhesion molecule-1 knockout (ICAM-1<sup>-/-</sup>) mice, 365
- Interferon-gamma, 246
- Interferon- $\gamma$  receptor-knockout mice, 365
- Interferon- $\gamma$  transgenic mice, 365
- Interleukin-1 (IL-1), 246, 308
- Interleukin-6 (IL-6), 8, 339
- Interleukin-10 (IL-10), 8
- Intermediately injured tissue, 221
- Intermediolateral cell column (IML), 333
- Internal elastic layer, 374
- International Association for the Study of Pain (ISAP), 17
- International normalized ratio (INR), 6
- International Small Animal Cardiac Health Council (ISACHC), 206
- Inter-renal aortic banding, 264
- Intersecting-slope technique, 98
- Interstitial myocardial fibrosis, 235
- Intimal hyperplasia, 311
- Intimal proliferation, 184
- Intimal thickness-related receptor (ITR), 358
- Intima-media thickness ratio, 159
- Intracardiac ganglion neurons, 151
- Intracardiac pacing, 69
- Intracarotid injections, 148
- Intracellular  $\text{Ca}^{2+}$ , 268
- Intracellular  $\text{Ca}^{2+}$  storage sites, 136
- Intracellular fuel sensing, 370
- Intracellular lipid content, 159
- Intracerebroventricular (i.v.c.) infusion, 335
- Intracisternally, 155
- Intraglomerular macrophage infiltration, 361
- Intramural coronary artery branching patterns, 221
- Intramyocardial catecholamine release, 139
- Intramyocardial lipid accumulation, 376
- Intramyocardial lipids, 377
- Intraobserver variability, 78
- Intrathecal infusion, 336
- Intrauterine growth-restricted induced hypertension, 281–283
- Intravascular balloon, 223
- Intravascular fibrinolysis, 376

Intravascular pressure, 95  
 Intraventricular conduction system, 136  
 Intrinsic renin-angiotensin system, 344  
 Intrinsic spectral broadening (ISB), 75  
 Introgressed Milan alleles, 271  
 Intron, 269  
 Inwardly rectifying potassium channels, 151  
 Ionic composition, 65  
 Ionized  $\text{Ca}^{2+}$ , 123  
 Ionized calcium, 120  
 Irish wolfhounds, 233  
 Ischemia-induced arrhythmias, 131  
 Ischemia/reperfusion (I/R) injury, 109, 219, 220, 356, 368  
 Ischemic ventricular fibrillation, 211  
 Isoflurane, 22, 28, 31, 36, 137–138  
 Isolated arterial microsomes, 161  
 Isolated atrial preparations, 144  
 Isolated atrial strip, 145  
 Isolated canine cardiac Purkinje fiber preparations, 149  
 Isolated coronary artery vascular strips, 145  
 Isolated guinea pig myocytes, 139  
 Isolated heart preparations, 109–127  
 Isolated papillary muscle, 65, 142  
 preparations, 144, 146  
 Isolated perfused frog heart, 109  
 Isolated perfused lower lobe of the cat lung, 142  
 Isolated rabbit hearts, 132  
 Isolated rat hearts, 154  
 Isolated working hearts, 220  
 Isolated working in situ heart-lung preparation, 114  
 Isolated working left heart preparation, 114  
 Isoleucine, 159  
 Isometric tension, 155  
 Isoprenaline-induced vasodilation, 261  
 8-Iso-prostaglandin  $\text{F}2\alpha$ , 261  
 8-Isoprostane, 381  
 Isoproterenol, 133, 214  
 Isoproterenol-induced hypertrophy, 185  
 Isotropy, 66  
 Isovolumic contraction, 104  
 Isovolumic relaxation, 86  
 IUGR-induced hypertension, 281  
 Ixodes scapularis, 208

## J

Japanese black cattle, 235  
 Japanese monkeys (*Macaca fuscata*), 338  
 Japanese white rabbits, 220, 314  
 JCR:LA-*cp* rats, 316  
 Jervelle and Lange-Nielsen syndrome, 211

JNK, 367  
 JT, 68  
 $\text{JT}_c$ , 68  
 Junctin (JCN), 371  
 Junctin overexpression, 371  
 Junctional adhesion molecule-1, 339  
 Junctional brady-arrhythmias, 149

## K

Kainic acid, 332  
 Kallikrein, 271  
 Kanamycin, 187  
 Kappa mRNA, 338  
 Kappa-opioid analgesics, 21  
 $\text{K}^+$  ATP channel activity, 152  
 $\text{K}^+$  ATP channels, 261  
 $\text{K}^+$  ATP-mediated pulmonary vasorelaxation, 151  
 2K1C and 1K1C renovascular hypertension models in mice, 263–264  
 $\text{K}^+/\text{Cl}^-$  co-transporter KCC3, 379  
 1K1C rabbits, 265  
 1K1C renovascular hypertension in dogs, 265  
 $\text{K}^+$  currents, 164  
 Keshan disease, 209  
 Ketamine, 22, 23, 35, 36, 150–151  
 Ketamine + acepromazine, 175–176  
 Ketamine, combination with tranquilizers, 175  
 Ketamine + diazepam, 31, 178–179  
 Ketamine/medetomidine, 27  
 Ketamine+ valiumR, 22, 28  
 Ketamine + xylazine, 22, 28, 176–178  
 Ketamine + xylazine + acepromazine, 23  
 Ketamine + xylazine + buprenorphine, 178  
 Ketamine + xylazine + guaifenesin, 178  
 Ketoprofan, 183  
 Ketoprofen, 26, 30, 34, 36, 37  
 Ketorolac, 26  
 k haplotype, 269  
 2-Kidney, 1-clip hypertension model, 236  
 Kidney rennin, 232  
 1-Kidney, 1-wrap model, 264  
 Kinases, 357–358  
 Klebsiella pneumoniae, 210  
 Knock-in mice, 205, 213, 243  
 Krebs, H.A., 120  
 Krebs-Henseleit buffer, 123  
 KUR-1246, 158  
 Kv1.5, 213  
 Kv4.3  $\text{K}^+$  channel, 140  
 KvLQT1/minK  $\text{K}^+$  channel, 140

**L**

- Lacrimation, 150
- Lactate dehydrogenase, 165
- Lactate/pyruvate ratio, 134
- LacZ, 213
- LAD coronary artery, 154
- Lagrangian strain, 66
- Lameness, 34
- Lamin A/C gene, 243
- Lamina terminalis, 342
- Langendorff
  - method, 109
  - perfused cat hearts, 170
  - perfused isolated rabbit hearts, 169
  - perfused isolated rat hearts, 220
  - preparation, 112
- Langendorff-type
  - perfused working left heart preparation, 115, 117
  - retrograde flow-regulated perfusion preparation, 114
  - retrograde pressure-regulated perfusion preparation, 112
- L-arginine, 262
- Lateral hypothalamus (LH), 331
- Lateral parabrachial nucleus (LPBN) and the dorsal raphe nucleus (DRN), 343
- Lateral tegmental field (LTF), 331
- Law of the heart, 111
- L-carnitine ( $\beta$ -hydroxy- $\gamma$ -N-trimethylammonium-butyrate), 279
- LDLR<sup>-/-</sup>:ACAT2<sup>-/-</sup>double knockout mice, 321
- LDLR<sup>-/-</sup>:ApoB CI<sup>-/-</sup>mice, 321
- LDLR<sup>-/-</sup>:ApoB CI<sup>-/-</sup>mice, 321
- LDLR<sup>-/-</sup>mice, 319
- LDLR<sup>-/-</sup>mouse is crossed with the ob/ob mouse, 321
- LDLR<sup>-/-</sup>:RAG1<sup>-/-</sup>mice, 321
- Ldlr triple-knockout (Ldlr 3KO) mice, 290
- Lean Zucker rats, 273
- Learned behavior, 24
- Learning, 24
- Lecithin-cholesterol, 317
- Lectin-like oxidized low-density lipoprotein receptor (LOX), 641
- Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1<sup>-/-</sup>) knockout mice, 275
- Left anterior descending coronary (LAD), 224
- Left circumflex coronary artery, 224
- Left subclavian artery to pulmonary artery shunts, 237
- Left-to-right shunting PDA, 203
- Left ventricular dP/d<sub>tmax</sub>, 132
- Left ventricular +dP/dt (LV +dP/dt), ranges of, 55
- Left ventricular-dP/dt (LV-dP/dt), ranges of, 55
- Left ventricular end-diastolic volume (LVEDV), ranges of, 56
- Left ventricular fractional shortening (LVFS), ranges of, 55
- Left ventricular hypertrophy, 206, 208
- Left ventricular mass/body weight (LV/body wt), ranges of, 58
- Left ventricular myocardium, 158
- Left ventricular peak systolic pressure (LVPSPP), ranges of, 55
- Left ventricular power (LVPower), ranges of, 57
- Left ventricular preload recruitable stroke work (LV-PRSW), ranges of, 56
- Left ventricular segmental shortening (LVSS), ranges of, 56
- Left ventricular stroke work, 176
- Left ventricular time constant of relaxation ( $\tau$ ), ranges of, 58
- Left ventricular/vascular coupling, 102
- Left ventricular velocity of shortening (LVVS), ranges of, 55
- Left ventricular volumes, 77
- Lemakalim-induced pulmonary vasorelaxation, 152
- Length, 65
- Lens focusing parameters, 73
- Lepob/ob:ApoE<sup>-/-</sup>, 318
- Leptin, 292, 346
- Leptin obR system, 317
- Leptin receptor-positive hypothalamic neurons, 323
- Less activity, 37
- Leukocytes, 210
  - activation, 263
  - adhesion molecule, 339
- Leukocytosis, 210
- Leukopenia, 210
- Levcromakalim-induced decrease in [Ca<sup>2+</sup>]<sub>i</sub>, 132
- Level of hydration, 24
- Levobupivacaine, 182
- Levomepromazine, 163
- Levomethadone, 37, 145
- Levorphanol, 28
- Levothyroxine, 240
- Lewis and Milan strains, 271
- Lexan plastic, 222
- L-glutamate, 335
- L-glutamate, 335

- Licking or biting of the affected area, 34  
 Lidocaine, 26, 30, 182  
 Ligation of coronary vessels, 207  
 Limbic system, 150  
 Lines per frame, 73  
 Lipid-based nano-particles, 210  
 Lipid-laden macrophages (foam cells), 308  
 Lipid metabolic dysregulation, 245  
 Lipid peroxides, 359, 368  
 Lipid storage disorder, 313  
 Lipoatrophic mice, 290  
 Lipoclin-type prostaglandin D(2) synthase (L-PGDS)<sup>-/-</sup> mice, 322  
 Lipopolysaccharide (endotoxin), 124  
   induced hypotension, 337  
   induced inflammatory responses, 356  
   induced toxicosis, 365  
 Lipoprotein lipase (LPL1), 317, 322  
 Lipoproteins, 308  
 Lipoprotein triglyceride uptake, 366  
 Liposomal drugs, 210  
 Lipotoxic cardiomyopathy, 245  
 5-Lipoxygenase, 294  
 12-Lipoxygenase expression, 138  
 Lithium, 168  
 Liver  
   cirrhosis, 240  
   cirrhosis models of cardiomyopathy, 240  
   sinusoidal endothelial cells, 363  
 Local anesthetic agents, 182  
 Local conduction velocities, 69  
 Localized IL-10 gene therapy, 127  
 Locus coeruleus (LC), 332, 339  
 Loesch, J., 259  
 Lofepamine, 167  
 Long axis displacement of the mitral annulus, 68  
 Longitudinal extensibility (EI), 96  
 Longitudinal motion and strain, 95  
 Long QT syndrome (LQTS), 369  
 Lortalamine, 171  
 Low-carbohydrate/high fat or high-starch diet, 272  
 Low compliance transducers, 70  
 Low-density cholesterol, 159  
 Low-density lipoprotein (LDL<sup>-/-</sup>), 308, 367–368  
 Low-density lipoprotein (LDL) cholesterol, 308  
 Low-density lipoprotein receptor-deficient (LDLr<sup>-/-</sup>), 208  
 Low-density lipoprotein receptor-deficient apolipoprotein B-100-only (LDLr<sup>-/-</sup>-ApoB100/100), 208  
 Low density lipoprotein receptor knock out (LDL-R<sup>-/-</sup>) mice, 362  
 Low-dose intravenous local anesthetics, 21  
 LOX-1<sup>-/-</sup>, 321  
 LOX-1<sup>-/-</sup> mice, 641  
 LR11 (also designated sorLA), 322  
 L-thyroxine, 240  
 L-type Ca<sup>2+</sup> channels, 337, 343  
 L-type Ca<sup>2+</sup> currents, 165  
 L-type voltage-gated Ca<sup>2+</sup> channels, 132, 133  
 Luciferase, 355, 369  
 Luciferase reporter gene, 280, 355  
 Ludwig, Carl, 109  
 Lumped compliance, 93  
 Lumped resistance, 93  
 Lung eNOS expression, 293  
 Lupus prone strain of mice, 322  
 LVdP/dt, 176  
 Lyme disease, 208  
 Lymphocyte trafficking, 355  
 Lymphocytic choriomeningitis virus (LCMV), 323  
 Lymphotoxin- $\alpha$ <sup>-/-</sup> mice, 409  
 Lysine, 268  
 Lysophosphatidic acid (LPA) receptors, 285  
 Lysosomal lipase hydrolysis, 160  
 LZ/ApoE<sup>-/-</sup> transgenic mice, 368  
 LZ-TG mice crossed with ApoE<sup>-/-</sup> mice (LZ/ApoE<sup>-/-</sup>), 368
- M**  
*Macaca mulatta* (rhesus monkeys), 178  
 Macromolecular leak, 132  
 Macrophage colony-stimulating factor (M-CSF), 274, 375  
 Macrophage infiltration, 239  
 Macrophages, 367, 374  
 Macula densa cells, 273, 340  
 Magnesium  
   restriction, 220  
   supplementation, 277  
 Magnetic resonance imaging (MRI), 82  
 Magnocellular neurons, 339  
 Maine Coon and Maine Coon crossbred cats, 232  
 Major histocompatibility complex (MHC), 362  
 Major histocompatibility complex gene knockout (MHC-II<sup>-/-</sup>) mice, 362  
 Maladaptive cardiac hypertrophy, 286, 490  
 Malignant  
   arrhythmias, 211  
   hyperthermia, 3  
 Malondialdehyde, 165

- Malonyl coenzyme a decarboxylase inhibition, 220
- MAO inhibitor, 156
- MAP kinase ERK2 activity, 183
- MAPK pathways, 127
- Marker/reporter proteins, 355
- Mast cells, 185
- Maternal heart rate, 155
- Matrix metalloproteases (MMPs), 374
- Matrix metalloproteinase-1 (MMP-1), 246, 264
- Matrix metalloproteinase (MMP)-3, 409
- Maximal systolic elastance ( $E_{max}$ ), 85
- Maximum and minimum values of the first derivatives of pressure ( $dP/d_{t_{max}}$  and  $dP/d_{t_{min}}$ ), 70
- Maximum diastolic potential, 136
- Maximum repetition frequency, 73
- Maze testing, 24
- 6-Mbp region on rat chromosome 2, 269
- Mdm2, 244
- Measuring diastolic dysfunction, 86–87
- Mechanical impedance (Z), 96
- Mechanical properties of cardiac muscle, 66
- Mechanisms, 114
- Meclofenamate, 183
- Medetomidine, 22, 23, 33, 36, 156
- Medetomidine + buprenorphine + ketamine, 173
- Medetomidine + butorphanol, 33, 173
- Medetomidine + butorphanol + midazolam, 173
- Medetomidine + hydromorphone, 33, 174
- Medetomidine + ketamine, 174
- Medetomidine + ketamine + midazolam, 175
- Medetomidine + midazolam, 174
- Medetomidine + propofol+ sevoflurane, 35
- Medetomine + propofol, 35
- Medial paralemnisal nucleus (MPL), 331
- Medial vestibular nucleus (MVe), 335, 343
- Median preoptic nucleus (MnPo), 274, 342
- Medulla oblongata, 338
- Medullary blood flow autoregulation, 276
- Medullary catecholamine systems, 336
- Medullary control region, 333
- Medullary reticular formation region (MRFR), 331–332
- Mefenamic acid, 153
- Megakaryocyte maturation, 378
- Melatonin (MT), 332, 342
- Melatonin-2 (MTR-2) receptor, 332, 342
- Meloxicam, 26, 183
- Membrane oxygenator, 113
- Membrane permeability, 162
- Membrane-spanning auxiliary protein subunit of voltage-gated  $Ca^{2+}$  channels, 342
- Memory, 24
- Menopause, 274, 357
- Meperidine (demerol), 28, 35, 144
- Meptazinol, 148
- Mesencephalic locomotor center, 331
- Mesenchymal cells, 141
- Mesenteric resistance, 134
- Mesenteric vessel vasomotion, 132
- Metabolically active tissues, 65
- Metabolic demands, 65, 232
- Metabolic “poisoning”, 125
- Metabolic syndrome, 307, 361–362
- Metabolic waste, 125
- Metabotropic receptors, 335
- Metalloproteinase-10 (ADAM-10), 310
- Metalloproteinase-17 (ADAM-17) mRNA expression, 374
- Metalloproteinases, 373–374
- Methadone, 144
- Methimazole, 23
- Methionine, 268
- Methionyl-tRNA synthetase, 323
- Methohexitone sodium, 23
- Methoxyflurane, 135
- Metocurine iodide, 185
- Metomidate, 153
- Metomidate + azaperone, 172–173
- Metoprolol, 245
- Mg+2 depletion, 279
- MHC class II-disparate mice, 363
- 15-7-MHz Broadband linear transducer, 77
- 15-MHz linear-array, 78
- 13-MHz linear array transducer, 78
- 15-MHz linear array transducer, 77
- 13-MHz linear scanner, 77
- 15-MHz linear transducer, 77
- 12-5-MHz phased-array transducer, 77
- 30-MHz transducer, 79
- Mice, 4–8, 23, 55–58, 340
- cardiac overexpression of canine caldesmon (CSQ), 374
  - cardiac-specific expression of soluble Fas (sFas), 373
  - cardiac specific overexpression of GRK-3, 358
  - deficient in gp91phox, 358
  - deletion mutant of cNCX ( $\Delta$ 680-685), 364
  - deletion of adenylyl cyclase type V ( $AC-V^{-/-}$ ), 359
  - glucose intolerance, models, 317–318
  - harboring targeted deletion of the ELN gene ( $ELN^{+/-}$ ), 376
  - heart-specific overexpression of both triadin and junctin, 371

- increased or decreased phosphoinositide 3-kinase (PI3K) activity, 358
- models of glucose intolerance, 317–318
- NF-kappa-B subunit p50 knocked out (p50/NF-kappa-B<sup>-/-</sup>), 369
- specifically overexpressing NCX, 364
- targeted disruption of the KCC3 gene (KCC3<sup>-/-</sup>), 379
- with targeted disruption of the KCC3 gene (KCC3<sup>+/-</sup>), 379
- transgenic for lysozyme (LZ-TG), 368
- transgenic overexpression of CaMKII-delta-C, 373
- venous malformations, 378
- Mice expression
  - canine cNCX, 364
  - lacZ coding DNA under the control of the Cx45 promoter, 372
  - luciferase reporter, 369
  - non-cleavable transmembrane form of TNF, 409
  - nuclear beta-galactosidase, 127
- Mice lacking
  - p47phox subunit of the NADPH oxidase (p47phox<sup>-/-</sup>), 359
  - T and B cells (RAG-1<sup>-/-</sup>), 380
- Micelles, 210
- Mice overexpression(ing)
  - angiotensinogen, 366
  - canine cardiac Na<sup>+</sup>/Ca<sup>2+</sup> exchanger (cNCX), 364
  - cardiac-specific dominant-negative glycogen synthase kinase- $\beta$  (GSK-3- $\beta$ DN), 358
  - cardiac specific Lats2, a serine/threonine kinase, 357
  - cardiac-specific TNF- $\alpha$  or  $\beta$ , 409
  - catalase, 219
  - cNCX, 364
  - dominant-negative Lats2, 357
  - eNOS (eNOS-Tg), 320
  - epithelial FABP in adipose tissue, 362
  - fast-twitch skeletal muscle TnT, 370
  - GLUT-4 only in adipose tissue (AG-4-TG), 361
  - GTP-cyclohydrolase I (GCH-Tg), 320
  - Kv1.1N206Tag in the heart, 213
  - native full-length APN, 361
  - parathyroid hormone type-1 receptor (PTH1R), 289
  - PPAR- $\alpha$ , 366
  - PPAR- $\alpha$  (PPAR- $\alpha$ -TG), 366
  - regulatory  $\alpha$ -subunit of AMP-activated protein kinase (PPKAG2), 358
  - terminal enzyme of aldosterone biosynthesis, 379
  - wild-type or DCM mutant [TG (K210Delta) Tnnt2, 243
- Mice that do not express PBL, 370
- Mice transgenic, for lysozyme (LZ-TG), 368
- Mice with overexpression
  - ardiac MMP-1, 374
  - cardiomyocyte Ca<sup>2+</sup>/calmodulin-dependent myosin light chain kinase, 358
  - Cav-1, 368
  - eNOS, 360
  - human sarcolemmal Na<sup>+</sup>/H<sup>+</sup> exchanger (hNHX), 364
  - junction (JCN-TG), 371
  - NCX, 364
  - protein phosphatase-1 (PP-1) glycogen-targeting subunit (PTG), 362
  - PTH1R, 380
  - rat angiotensinogen, 366
- Microalbuminuria, 307
- Microcirculatory flow, 225
- Microcirculatory obstructions, 225
- Microphone, 85
- Microsatellite markers, 233
- Microsomal prostaglandin E synthase-1 (mPGES-1), 272
- Microsomal transfer protein, 317
- Microvascular studies, 143
- Midazolam, 38
- Midazolam (versed), 153–154
- Midazolam + butorphanol, 179
- Midazolam + fentanyl + fluanisone, 179
- Midazolam+ ketamine, 35
- Midazolam+ ketamine+ butorphanol, 35
- Midazolam + methadone + propofol + isoflurane + continuous infusion of propofol and fentanyl, 179
- Migrating larval forms, of parasites, 207
- Milan alleles, 271
- Milan SHR, 268
- Millar catheter-tip manometer, 70
- Millar instruments, 84
- Milrinone, 159
- Minaprine, 171
- Mineralocorticoid receptor (MR), 282, 291
- Miniature Schnauzers, 211
- Minimum alveolar concentration (MAC), 20
- Minute ventilation, 175
- Minute volume, 176
- miR-133, 213



- Mitochondria(al)  
  adenosine triphosphate-sensitive K<sup>+</sup>  
  channels, 152  
  dysfunction, 160  
  GR (mito-GR-GFP), 322  
  K<sup>+</sup> (ATP) channels, 138  
  membranes, 370  
  metabolism, 358  
  oxidative damage, 244  
  oxidative phosphorylation, 163  
  respiratory, 161  
  respiratory enzyme complex-1, 336  
  size, 159  
  Mitochondrial-derived ATP production, 377  
  Mitogen-activated protein kinase (MAPK), 286  
  Mitral endocardiosis, 206  
  Mitral insufficiency, 203, 207  
  Mitral regurgitation, 205, 206  
  Mitral valve, 86  
  prolapse, 205  
  regurgitation, 203  
  35 mM KCl-induced increases in [Ca<sup>2+</sup>], 164  
  MMP-9 activity, 158  
  MMP-9/gelatinase, 409  
  MNK-mutant mice, 374  
  Model of type-2 diabetes, 290  
  Modified Krebs buffer, 159  
  Modulating cardiovascular function, 335  
  Moens-Korteweg equation, 93, 98  
  Monckeberg's medial sclerosis, 313  
  Monensin, 239  
  Monoamine transporter system, 220  
  Monocrotaline (MCT), 293  
  Monocrotaline-induced pulmonary  
  hypertension, 293–294  
  Monocyte chemoattractant protein-1 (MCP-1),  
  339, 373  
  Monocyte chemotactic protein (MCP)-1, 308  
  Monocyte/macrophage lineage, 375  
  Monoexponential function ( $\beta$ ), 86  
  Monosynaptic reflexes, 154  
  Morphine, 27, 28, 36, 141–144  
  Morphine preconditioning, 143  
  Motion-mode (M-mode), 71  
  Mouse strains deficient in the HDL scavenger  
  receptor Class B Type 1 (SR-B1), 319  
  Moustached tamarins (*Saguinus mystax*), 235  
  Movement changes, 33  
  Moxifloxacin, 187  
  Moxonidine, 360  
  mREN.Lewis rat, 291  
  mREN-2 model, 283  
  mREN-2 (hypertensive) rats, 342  
  mREN-2 transgenic rat, 283  
  MRI imaging, for detection of ventricular/  
  vascular coupling, 104  
  mRNA levels of VCAM-1, 361  
  Msx2, 362  
  Muco-ciliary clearance, 21  
  Mulberry heart, 239  
  Multifocal, 208  
  Multifocal hyaline necrosis, 239  
  Multimeric tandem repeat element, 269  
  Multi-phase reflex responses, 333–334  
  Multiple linear regression analysis (analysis  
  of covariance), 67  
  Multiple linear regression techniques, 68  
  Multiple slice technique, 80  
  Multiple transgenic models, 290  
  Munich-Wistar rats, 279  
  Mu-opioidergic analgesic (morphine), 21  
  Mu-opioid receptors, 346  
  Mu-receptor mRNA, 338  
  Murine cysticercosis model of  
  cardiomyopathy, 240  
  Murine IL-10, 409  
  Murine plasma fibrinolytic system, 321  
  Murine plasminogen, 321  
  Muscarinic, 185  
  Muscle  
  glucose oxidation, 362  
  insulin-stimulated/threonine protein  
  kinase, 312  
  LIM protein, 244  
  RING finger 1 (MuRF1), 242  
  specific deletion of Ptpn11, 243  
  Mus81 endonuclease gene, 208  
  Mutant  
  cTnT (R141W), 243  
  *fa* gene, 315  
  serum response factor, 246  
   $\alpha$ -tropomyosin (TM), 242  
  Mutated leucine zipper domain (CREB-  
  S133A-LZ), 376  
  Mutilation, 18  
  mXin- $\alpha$ -null mice [mXin- $\alpha$  (-)], 242  
  Myeloid cell leukemia-1, 358  
  Myeloperoxidase activity, 368  
  Myocardia(al)  
  adenylate cyclase, 136  
  adrenergic receptor kinase ( $\beta$ -ARK-1), 360  
  contractility, 364  
  creatine transporter, 245  
  dysfunction, 271  
  fibrosis, 409  
  infarction, 87  
  related SRF coactivators, 243  
  resistivity, 85



- thrombin signaling, 357
- VEGF protein expression, 143
- Myocardial oxygen consumption (MyoVO<sub>2</sub>), ranges of, 57
- Myocardial performance index (MPI), 77, 79
- Myocardial stiffness index (k), 68
- Myocarditis, 208, 365
- Myoclonic twitching, 152
- Myocyte, 86
- Myocyte disarray, 231
- Myofilament
  - disarray, 242
  - sensitivity, 86
- Myogenic tone, 284
- β-Myosin heavy chain expression, 277
- Myxomatous mitral valve disease, 206
  
- N**
- Na<sup>+</sup>
  - channels, 182
  - conductance, 164
  - K<sup>+</sup>-ATPase pump inhibitor, 345
- Na<sup>+</sup>/Ca<sup>2+</sup> and Na<sup>+</sup>/H<sup>+</sup> exchangers, 364
- Na<sup>+</sup>/Ca<sup>2+</sup> exchanger (NCX), 139, 160
- NADPH oxidase, 284, 359, 366
  - activity, 283
  - subunit protein, 358
- Na<sup>+</sup>/H<sup>+</sup> exchanger, 293
- Na<sup>+</sup>-K<sup>+</sup>-Cl<sup>-</sup> co-transporter isoforms, 273
- Nalbuphine, 21, 28
- Naloxone, 28, 148–149
- Na<sup>+</sup> membrane conductance, 168
- Naproxen, 183
- Narcotics, 34
- Natriuretic peptide receptor (NPR)-A, 292
- Natriuretic peptide receptor type C (NPR-C), 341
- Natriuretic peptides, 341, 357
- Natural killer T (NKT) cells, 321
- Naturally occurring animal models of atherosclerosis, 311
- Naturally occurring cardiac arrhythmias, 211
- Naturally occurring, iatrogenic and transgenic models of atherosclerotic disease, 307–324
- Natural strain 66
- Navier-Stokes equations, 93, 100
- Naxos disease, 234
- NCX-mediated Ca<sup>2+</sup> influx, 139
- Necrotizing myocarditis, 208
- Negative inotropic effect, 131
- Neocortical blood flow, 279
- Neointimal formation, 375
- Neointimal lesions, 368
- Neomycin, 187
- Neoplasia, 208
- Neovascularization, 273
- Nephroangiosclerosis, 280, 355
- Nephrogenic period, 275
- Nephrosclerosis, 261
- Nerve growth factor (NGF), 338
- Neurogenic model of hypertension, 334
- Neurogenic tone, 135
- Neurogenic vasodilation, 348
- Neurohumeral control, 344
- Neurohumeral hyperactivation, 87
- Neurolept analgesia/anesthesia, 166, 172
- Neuromediators, 347
- Neuromodulator, 337, 344
- Neuromuscular blocking agents, 185–186
- Neuronal ATP-sensitive K<sup>+</sup> channels (KATP), 339
- Neuronal density, 278
- Neuronal excitability, 339
- Neuronal nicotinic acetylcholine receptor, GABAA-receptor delta, 344
- Neuropeptides, 335, 342, 347
- Neuropeptide Y (NPY), 335, 346
- Neurotransmitter, 335, 337, 338, 341, 344, 347
- Neutral endopeptidase inhibition, 333
- Neutrophilic adhesion, 183
- Neutrophilic infiltration, 361
- New Zealand
  - rabbits, 238
  - strains of SHR, 268
  - white rabbits, 159, 171, 314
- New Zealand genetically hypertensive rat (NZGH), 268
- Nicotine, 101
- Nicotinic acetylcholine receptor (nAChR)-induced transients, 131
- Nicotinic acetylcholine receptor-induced transients in intracellular free Ca<sup>2+</sup> concentrations, 151
- Nicotinic acetylcholine receptors (nAChRs), 336
- Nicotinic receptors, 185
- Nitric oxide (NO), 133, 262
  - pathway, 132
  - signaling, 336
  - synthase, 360–361
  - synthase-2, 237
  - synthase activity, 263
  - synthesis blockade hypertension, 278–280
- Nitric oxide-releasing formulation of aspirin (NCX-4016), 184
- Nitrogen intake, 4

- Nitroglycerine, 134, 261
- Nitrous oxide  
  140N-methyl-D-aspartate receptor  
  (NMDA) antagonists, 21, 28, 343
- N-nitro-L-arginine, 139
- N-nitro-L-arginine methyl ester (L-NAME),  
  262, 278
- N<sub>2</sub>O (nitrous oxide), 32
- Nociception, 341
- Nociceptors, 18
- Nocturnal arterial blood pressures, 336
- Non-collagenous adhesion molecule, 378
- Non-Communicating Children's Pain  
  Checklist, 19
- Non-depolarizing muscle relaxant  
  (SZ1677), 186
- Non-depolarizing neuromuscular blocking  
  agent (GW280430A), 186
- Non-homogeneous material, 66
- Non-human primates, 311
- Non-obese diabetic mouse (NOD), 323
- Nonobligatory heterodimers, 370
- Non-selective cation channels, 273
- Non-steroidal anti-inflammatory agents  
  (NSAIDs), 183–185
- Noradrenergic neurons, 331
- Noradrenergic projections, 331
- Norepinephrine (NE), 234, 245
- Norepinephrine-induced cardiac oxidative  
  stress, 267
- Norepinephrine-induced expression  
  of cytokines, 118
- Norepinephrine turnover rates, 169
- Normal arterial pH, 3
- Normal blood chemistry, ranges for, 7
- Normal blood count parameters, ranges for, 5
- Normal cardiac function parameters, ranges  
  of, 55–57
- Normal coagulation parameters and blood  
  glucose, ranges for, 6
- Normal hematological and/or serum enzyme  
  levels, 1
- Normal levels, ranges of, 8
- Normal physiological parameters, 1–3
- Normal plasma electrolytes, ranges for, 6
- Normal ranges of blood flow distribution in  
  ml/min/100 gm tissue, 1, 58, 117, 119,  
  120, 122–125
- Normal rectal temperatures, ranges for, 5
- Normal red blood cell parameters, ranges  
  for, 5
- Normal sinus rhythm, 69
- Normal values for other cardiovascular  
  indices, ranges of, 58
- Nortriptyline, 167
- Noxious signals, 337
- N-3 polyunsaturated fat, 311
- NPY receptor  
  agonist, 346  
  antagonist, 346
- NSAIDs, 20, 26, 34
- Nuclear antigen-positive cells, 381
- Nuclear ER- $\alpha^{-/-}$  (ERKO) mice, 356
- Nuclear factor kappa-B (NF-kappa-B), 240,  
  246, 268, 369–370
- Nuclear membrane proteins, 243
- Nuclear Phox2b, 338
- Nucleus ambiguus, 333, 335, 342
- Nucleus cuneatus (Cu), 342
- Nucleus para-retroambiguus (NPRA), 343
- Nucleus tractus solitarius (NTS), 331,  
  337–339
- Null mutation of cNCX gene, 364
- Numeric rating scale (NRS), 19
- O**
- Obese SHR, 270
- Obese Zucker rats, 238, 273
- Obesity, 307, 361
- Obesity-linked insulin resistance, 361
- Obex, 142
- Obligate carnivores, 2
- ob/ob mouse, 318
- Observational studies, 24
- Occipital cortex, 279
- 25-OHD-1- $\alpha$ -hydroxylase (CYP27B1),  
  287, 380
- Okamoto-Aoki strain of SHR, 267
- Olanzapine, 167, 171
- Omacor, 290
- Omega-hydroxylase activity, 283
- One-kidney, one-clip (1K1C), 260
- Open field novelty stress, 170
- Opiate receptor antagonist, 345
- Opioid(s), 21, 27, 141, 345
- $\mu$ -Opioid agonist, 32
- Opioid-induced cardioprotection, 143
- $\mu$ -,  $\delta$ -, and  $\kappa$ -Opioid receptors, 338
- Opioid receptor sensitive pathways, 150
- Optimal arterial compliance, 100
- Optimal coupling, 100
- Optimal step size, 73
- Orexigenic neuropeptides, 347
- Orexin A, 347
- Orexin receptor-mediated excitation, 342
- Orexins, 342, 347
- Organum vasculosum, 342

- Origin of both great vessels from the right ventricle, 203
- Orphan nuclear receptors, 370
- Orthogonal imaging, 80
- Orthostatic hypotension, 167
- Oscar Langendorff, 109
- Osmolality, 273, 333, 340
- Osmo-mechanoreceptors, 333
- Osmotic minipumps, 274
- Osmotic stimulation, 337
- Osteopontin (OPN), 261, 378
- Ouabain, 132, 136, 345
- Ouabain-induced arrhythmias, 161, 168
- Ouabain-induced contractions, 160
- Ouabain-initiated hypertension, 278
- Ouabain-like substance, 268
- Ouabain-resistant  $\alpha(2)$ -Na<sup>+</sup>-K<sup>+</sup>-ATPase subunits, 280
- Ovalbumin (OVA)-specific immune tolerance, 362
- Ovariectomy, 272
- Ovarioectomized females, 344
- Ovariohistectomy, 147
- OVA-specific CD8<sup>+</sup> effector T cells, 363
- Overexpression
  - of ATR-2, 336
  - of  $\beta$ -ARK-1 COOH-terminal inhibitor peptide ( $\beta$ -ARK-1<sup>-/-</sup>/ $\beta$ -ARK-1ct), 360
  - of G-alpha(g), 245
  - GRK5, 284
  - of hyperpolarization-activation cyclic nucleotide-gated channel gene, 214
  - of IL-10 by T cells, 409
  - of MMP-1, 264
  - models, 245–246, 317
  - of nuclear coactivators, 356
  - of TBX-5, 377
- Oxidases, 358–359
- Oxidative carbohydrate utilization, 157
- Oxidative phosphorylation, 152, 161
- Oxidative stress, 208
- Oxygen (O<sub>2</sub>)
  - consumption, 102
  - saturation curve, 136
  - utilization ratio, 133, 177
- Oxygenases, 358–359
- Oxygen + nitrous oxide + halothane, 23
- Oxymorphone, 27, 28, 148
- Oxymorphone + bupivacaine, 181
- Oxymorphone+ diazepam, 31
- Oxytocin (OT), 337
  - receptor activation, 341
  - secretion, 340
- P**
- p22 (phox), 275
- p53, 239
- Paced atrial-HIS intervals, 145
- Pacemaker activity, 164
- Pachystigma pygmaeum, 239
- Pacing-induced CHF, 212
- Pacing thresholds, 68
- PaCO<sub>2</sub>, 133
- Pain and distress recognition, in rats and mice, 23
- Pain inhibition, 341
- Pain recognition
  - in animals, 17
  - in cats, 37
  - in dogs, 33–34
  - in guinea pigs, 38
  - in pigs, 41
  - in rabbits, 29
  - in rhesus monkeys, 45–46
- Pain-scoring systems, 19
- Pain treatment
  - in cats, 37–38
  - in dogs, 34–35
  - in guinea pigs, 38
  - in pigs, 41–42
  - in rabbits, 29–30
  - in rhesus monkeys, 46
  - in small ruminants, 44
- Palmoplantar keratoderma, 234
- Pancreatic insulin-producing  $\beta$ -cells, 307
- Pancreatic islet cells, 307
- Pancronium, 154
- Pancuronium, 185
- P and QRS, 68
- Panic, 332, 336
- Papillary muscle, 164
- Papio papio (baboons), 209
- PAR-1, 373
- PAR-1<sup>-/-</sup>, 373
- PAR-2, 373
- PAR-2<sup>-/-</sup>, 373
- PAR-3<sup>-/-</sup>, 373
- PAR-4, 373
- PAR-4<sup>-/-</sup>, 373
- Parabiosis experiment, 270
- Parabrachial nucleus (PBN), 331
- Paradoxical excitement, 141
- Parallel conductance offset (V<sub>c</sub>), 83
- Paralog neuropeptides, 347
- Parapyramidal region (PPR), 333
- Parasitic blood diseases, 1
- Parasternal short-axis view, 78
- Parasympathetic inhibition, 150

- Parathyroid hormone type-1 receptor (PTH1R), 380
- Parathyroid hormone type-1 receptor models, 289
- Paraventricular nucleus neurons (PVN), 154
- PAR-2<sup>-/-</sup> mice, 373
- PAR-4<sup>-/-</sup> mice, 373
- Paroxetine, 167
- Paroxysmal atrial tachycardia, 212
- Partial anomalous pulmonary venous drainage, into the right atrium, 203
- Passive diastolic stiffness, 86
- Passive diffusion, 379
- Pasteurella multocida, 314
- Patch-clamp techniques, 133
- Patent ductus arteriosus (PDA), 203
- Patient-controlled analgesia (PCA), 20
- Pavetta harboril, 239
- PDE4, 244
- Peak A-wave velocities, 77
- Peak E-wave velocities, 77
- Peak velocity, 75
  - of early left ventricular filling (E wave), ranges of, 57
  - of late left ventricular filling (A wave), ranges of, 57
- Pebax catheter, 70
- Pedunculopontine nucleus, 331
- Penicillin, 187
- Penicillin-related compounds, 187
- Pentazocine, 21, 28, 145
- Pentazocine (kappa-opioidergic agent), 21
- Pentobarbital, 131
- Pentobarbital sodium, 29, 31, 36
- Peptide inhibitor of G (q), 285
- Peptones, 337
- Per2 and bmal1 (clock genes), 342
- Perfluorochemicals, 120
- Perforin, 127
- Perfusate, 112
- Perfusate reservoir, 112
- Perfused carotid bodies from rabbits, 153
- Perfused cat heart, 110
- Perfusion solutions, 120
- Periaqueductal gray (PAG), 331, 340
- Pericardial effusion, 71
- Pericardial fluid, 183
- Pericardium, 87
- Periglomerular, 372
- Peripheral baroreceptor inputs, 333
- Peripheral chemoreflexes, 149
- Peritubular interstitium, 372
- Peroxisomal proliferator-activated receptor- $\alpha$ -regulated genes, 241
- Peroxisome proliferator-activated receptor (PPAR), 366
- Peroxisome proliferator-activated receptor- $\alpha$  (PPAR- $\alpha$ ), 245, 277
- Peroxisome proliferator-activated receptor agonists, 312
- Peroxisome proliferator-activated receptor- $\alpha$  knockout (PPAR- $\alpha$ <sup>-/-</sup>) mice, 286
- Peroxisome proliferator-activated receptor (PPAR)- $\gamma$ , 244
- Persian-cross cats, 36
- Persistent left 4th aortic arch, 203
- Persistent right aortic arch, 203
- Petrosal ganglion, 339
- PGF<sub>2</sub>, 162
- PGI<sub>2</sub>/thromboxane (TX) ratio 291
- pH, 133
- Pharmacodynamics, 118
- Phase distortion, 69–70
- Phencyclidine, 150
- Phenothiazine derivatives, 22, 160–163, 167
- Phenotyping, 67
- Phentolamine, 292
- Phenylalanine, 159
- Phenylbiguanide, 334
- Phenylbutazone, 20, 183
- Phenylephrine, 134, 213, 265
- Phenylephrine-induced contractions, 154
- Phenylindole derivative, 169
- Phosphate transfer, 356
- Phosphatidylinositol 3-kinase (PI3K)-Akt-nitric oxide synthase (NOS) signaling pathway, 338
- Phospho-Akt, 143
- Phospho-Akt kinase activity, 143
- Phosphodiesterase (PDE)-4, 293
- Phospho-Erk-1, 2, 143
- Phospho-ERK1/2, 289
- Phospho-Erk-1, 2 MAP kinase, 143
- Phospho-JNK, 289
- Phospholamban (PLB), 364, 372–373
- Phospholamban (PLN), 364, 372–373
- Phospholipase activation, 162
- Phospholipase C, 268, 337
- Phospholipid, 210
- Phospholipid transfer protein (PLTP), 379
- Phosphorylation of myosin light chain (MLC), 284
- Phox2b, 338
- Phrenic nerve activity, 154
- Physical examination, of each animal, 1
- Physiological dead space, 175
- Physiological modeling, 94
- Physiologic ventricular, 355

- Phytoalexin, 337
- Phytoestrogen feeding, 356
- Pigs, 55–58
- Pigs (2–6 months), 4–8
- Pigs transgenic
  - for human CD46 expression, 363
  - for human membrane co-factor protein (hMCP), 363
- Piloerection, 24
- P47 immunoreactivity, 343
- Pimozide, 169
- Pioglitazone, 225
- Piroxicam, 183
- Pithed rats, 142, 292
- Pituitary adenylate cyclase-activating polypeptide (PACAP), 336
- PKA, 143
- PKC, 143
- PKC-alpha, 133
- PKC-delta, 133
- PKC-epsilon, 133
- PKC-zeta, 133
- Plaque rupture, 309
- Plasma
  - cortisol levels, 147
  - histamine levels, 141
  - membrane ecto-enzyme, 368
  - renin activity, 134, 261
  - rennin concentrations, 132
  - volumes, 142
- Plasma angiotensin-II (Angio-II), 261
- Plasma N-terminal immunoreactivity (ANP-IR), 233
- Plasmin, 376
- Plasminogen activator inhibitor-1 (PAI-1), 316
- Plasticity, 344
  - of opioid receptor system, 141
- Plastic wrap, 264
- Platelet
  - adhesion, 223
  - dysfunction, 206
  - numbers, 3
- Play a decisive role, in fetal programming of hypertension induced by, 358
- Pleomorphic vesicles, 344
- Plication, 237
- p.Met532Arg mutant  $\alpha$ -MHC gene, 242, 243
- p42/44 mitogen-activated protein kinase, 242
- p38 Mitogen-activated protein kinase inhibitor, 366
- p53-negative regulator, 244
- Polled Hereford calves, 234
- Polycarbonate plugs, 222
- Polygonal cells, 316
- Polymorphic ventricular tachycardias, 211
- Polyomavirus middle T antigen (PyMT), 378
- Polystyrene microspheres, 238
- Polystyrene microspheres, 224
- Polyunsaturated fatty acids, 336
- Ponies, 174
- Ponto-medullary nucleus reticularis gigantocellularis (PMNGC), 332
- Poor or no self-grooming, 34
- Porcine atherosclerotic renovascular disease, 265
- Porcine-derived gelfoam, 238
- Porphyrin secretion or “red tears”, 24
- Portal hypertension, 184
- Portalization, 265
- Positive end-expiratory pressure (PEEP), 39
- Posterior hypothalamic (PH) area, 331, 342
- Posterior hypothalamic locomotor region (PHLR), 332
- Postmenopausal hypertension, 273
- Postoperative delirium, 156
- Postpartum cardiomyopathy (PPCM), 244
- Post-prandial hyperinsulinemia, 311
- Postrema, 274
- Post-rest potentiation, 364
- Postural changes, 33, 102
- Postures, 18
- Potassium, 3
- PPAR- $\alpha$  models, 286
- PPAR- $\alpha$ -TG mice, 366
- PPAR gamma ( $\gamma^{-/-}$ ), 244
- p42/p44 mitogen-activated protein kinase activation, 357
- PR, 68
- Pravastatin, 292
- Prazosin, 292
- Pre-anesthesia, 17–47
- Pre-anesthesia and anesthesia
  - in calves, sheep and goats, 42–43
  - in cats, 35–36
  - in dogs, 30–32
  - in guinea pigs, 38
  - in pigs, 39
  - in rhesus monkeys, 45
- Preconditioning, 225, 358
- Predatory threats, 341
- Pre-eclampsia, 273
- Pre-ejection period, 133
- Preload, 65
- Preload dependence of cardiac output, 109
- Preload-recruitable stroke work, 103
- Prenatal protein restriction, 282
- Preoptic area, 344
- Prepro-endothelin-1, 271

- Pressor response region, 333  
 Pressor responses, 149  
 Pressure overload, 236  
 Pressure phase plane (PPP), 104  
 Pressure-regulated system, 112  
 Pressure-Volume relationship, 67–68  
 Previously instrumented pregnant ewes, 144  
 Previously instrumented sheep, 146  
 Primary hypertension, 260  
 Primate models of atherosclerosis, 311  
 Primates (rhesus), 4–8, 55–58  
 P-R interval, ranges of, 58  
 Proapoptotic type-II transmembrane protein, 373  
 Proarrhythmic, 163  
 Proatrial natriuretic peptide (pro-ANP), 287, 374  
 Pro-atrial natriuretic peptide gene disrupted mouse, 375  
 Problem solving behaviors, 24  
 Prochlorperazine (thioridazine), 163  
 Proenkephalin A, 338  
 Proenkephalin A-related immunoreactive neuronal perikarya, 338  
 Proenkephalin B, 338  
 Profibrotic cytokine TGF- $\beta$ , 275  
 Pro-fibrotic phenotype, 409  
 Profilin models, 289  
 Profilin-1 overexpressed mice, 289  
 Progesterin receptor activation, 344  
 Progestins, 344  
 Programmed electrical stimulation, 235  
 Proinflammatory cytokines, 225  
 Pro-inflammatory signaling, 409  
 Prolactin, 244  
 Prolate ellipsoid, 80  
 Prolate ellipsoid model, 77  
 Proliferative marker Ki-67, 273  
 Proline, 268  
 Prolongation of the QT interval, 369  
 Prolonged action potentials, 369  
 Prolonged pain, 17  
 Promazine, 160  
 Promoter genes, 355  
 Propagation of JGA vascular signals, 372  
 Propiomelanocortin (POMC), 338  
 Propofol, 31, 36, 127, 132–133  
 Propofol + fentanyl, 32  
 Propoxyphene, 28  
 Propylene glycol, 152, 187  
 Prorenin receptor, 261  
 Prostaglandin G/H synthase-2 (PGHS-2, also known as COX-2), 184  
 Protease-activated receptors (PARs), 373  
 Proteases, 373–374  
 Protein identified as Fh1-1, 293  
 Protein kinase-2 (CK-2), 366  
 Protein kinase A (PKA), 337, 370  
 Protein kinase A phosphorylation, 87  
 Protein kinase B/Akt signaling, 138  
 Protein kinase C, 139, 213, 220, 277  
 Protein kinase C-delta (PKC), 139  
 Protein kinase C-delta knockout (PKC-delta<sup>-/-</sup>) mice, 358  
 Protein kinase C (PKC)-epsilon, 245  
 Protein kinases, 133  
 Protein restriction, 282  
 Protein tyrosine phosphatase (PTP), 243  
 Proteomic profiles, 271  
 Prothrombin time (PT), 6  
 Protriptyline, 167  
 Proximal pulmonary arterial constriction, 103  
 PS and PDA, combined, 203  
 Pseudopodia formation, 154  
 Pseudopregnant females, 205  
 Psycho emotional conditions, 24  
 Psychological stress, 270  
 Psychological stressors, 332, 336  
 Psychotropic agents, 22  
 PTH/PTH-related protein (PTHrP), 380  
 PTH1R overexpression, 380  
 PTHrP/PTH1R system, 380  
 PTHrP/TTH1R<sup>-/-</sup>mice, 380  
 Pulmonary arterial wedge pressures, 147  
 Pulmonary artery vascular rings, 152  
 Pulmonary C fibers, 334  
 Pulmonary edema, 111  
 Pulmonary endothelial cells, 360  
 Pulmonary function, 39  
 Pulmonary hypertension, 102, 206, 207, 210  
 Pulmonary resistance (Rpa), ranges of, 56  
 Pulmonary vascular resistance, 174  
 Pulmonic stenosis (PS), 203, 204  
 Pulse interval, 334  
 Pulse repetition frequency (PRF), 76, 80  
 Pulse wave velocity, 93, 94, 97–99  
 Pulsus alternans, 234  
 Pump function, 65, 221  
 Purinergic receptor, 368, 374  
 Purkinje and granular cells, 338  
 Purkinje fiber preparations, 137, 164  
 Purring, 37  
 Putative autoimmune disease, 231  
 P2X4R, 374  
 Pyridylcarbinol, 159  
 Pyruvate, 124

**Q**

QRS, 68  
QRS duration, ranges of, 58  
QTc, 68, 165  
QT prolongation, 163  
Quackenbush Swiss mice, 280  
Quadrature Doppler signals, 104  
Quantitative trait loci (QTL), 259  
Quetiapine, 167

**R**

Rabbits, 4–8, 55–58  
    hypercholesterolemia, 310  
    models, 313–314  
Rac-bupivacaine, 182  
Rac-thiopental, 132  
Radionuclide ventriculography, 81–82  
Radio-opaque markers, 80, 224  
Ragdoll cats, 232  
Ramipil, 277  
Range-gated pulse, 104  
Range resolution, 72, 80  
Ranke model, 101  
Rapacuronium, 185  
Rapid atrial pacing, 207, 212  
Rapid cardiac pacing, 236  
Rapidly activating delayed rectifier  
    K<sup>+</sup> current, 163  
Rapid vena caval occlusions, 87  
Rapid ventricular filling, 86  
Rapid ventricular pacing, 207, 212  
Rat chromosome-1, 266  
Rat chromosome-2, 259  
Rat chromosome-10, 270  
Rate, 65  
Rate-pressure product, 149  
Rat hindquarter preparation, 161  
Rat insulin promoter (RIP)-mOVA mice, 362  
Ratio of pre-ejection period and ejection  
    time, 133  
Ratio of ventricular end-systolic pressure and  
    stroke volume (Pes/SV), 102–103  
Rat models, 315–316  
Rats, 4–8, 23, 55–58  
Rauwolfia derivatives, 158–160  
RBC rheological properties, 262  
Reactive oxygen species (ROS), 139, 272, 335  
Real-time linear array, 72  
Receptor  
    activity-modifying protein, 338  
    subtypes, 356, 359  
Receptor for advanced glycation end-products  
    (RAGE), 126  
Recognition and treatment, of pain and  
    distress, 17–47  
Recognition of pain in small ruminants, 43–44  
Recombinant adenovirus, 264  
Recombinant human M-CSF, 375  
Recombinase-mediated cassette exchange, 205  
Recumbency, 18  
Red blood cell (RBC) deformability, 262  
Reduced fatty acid, 376  
Reendothelialization, 357  
Reference oscillator, 104  
Reflex cardio-inhibitory responses, 334  
Reflex inhibition of renal sympathetic nerve  
    activity, 334  
Reflex responses to exercise, 332  
Reflex tachycardia, 161  
Refractory periods, 69, 136, 161  
Regional ischemia, 219  
Regucalcin, 362  
Regucalcin transgenic (RC-TG) rats, 362  
Relaxin, 244  
Reliability of ultrasound data, 80  
Remifentanil, 150  
Remifentanil HCl, 32  
Renal arterial flow, 139  
Renalase, 271  
Renal cortex, 279  
Renal cortical NADPH oxidase, 275  
Renal cortical tubulointerstitial injury, 381  
Renal epoxygenase activity, 283  
Renal monocyte/macrophage infiltration, 381  
Renal phosphodiesterase 4B4, 271  
Renal sympathetic nerve activity, 132, 133  
Renal tubular cytochrome P450-4a  
    expression, 277  
Renal vascular dilation, 144  
Renin-angiotensin-aldosterone system  
    (RAAS), 271  
Renin-angiotensin system (RAS), 231, 259,  
    344, 366  
Renopressin, 265  
Renovascular hypertension, 260–266  
    models in rabbits, 264–265  
    in pigs, 265–266  
Renovascular (2K1C) hypertension, 262  
Renovascular two-kidney, one-clip  
    (2K1C), 260  
Reperfusion injury, 135  
Replication-deficient adenovirus, 294  
Repolarization abnormalities, 160  
Repolarizing delayed rectifier  
    K<sup>+</sup> current, 212  
Reserpine, 22, 158–160, 292  
Reserpine-induced ptosis, 171



- Respiratory acidosis, 173  
 Respiratory depression, 152  
 Respiratory rate, 5, 24  
 Response to ataxia, 141  
 Resting potential, 164  
 Resting sympathetic drive, 279  
 Restlessness, 18  
 Restriction, 358  
 Restriction fragment length  
   polymorphism, 269  
 Resveratrol, 220, 337  
 Reticular activating, 150  
 Reticuloendothelial system, 313  
 Retinal layer thinning, 378  
 Retinopathy, 315  
 Retrograde perfusion preparations, 112  
 Retrograde ventricular effective refractory  
   periods, 145  
 Retrospective B-scan imaging (RBI), 76  
 Retrospective color flow imaging (RCFI), 76  
 Reverse cholesterol transport (RCT), 379  
 R120G mutation, 245  
 Rhesus monkeys, 163, 311  
 Rheumatic heart disease, 235  
 Rho A, 225  
 Rhodopsin, 358, 378  
 Rhodopsin-like G-protein-coupled receptor  
   superfamily, 358  
 Rhodopsin promoter, 378  
 Rho-kinase, 225, 272, 333  
 Rho/Rho kinase, 284  
 Right ganglionated plexus, 212  
 Right ventricular angiography, 80  
 Right ventricular cardiomyopathy, 211  
 Right ventricular function, 140  
 Right ventricular mass/body weight (RV/body  
   wt), ranges of, 58  
 Right ventricular/pulmonary artery  
   coupling, 102  
 Right ventricular volumes, 81  
 Rilmenidine, 155, 265, 333, 360  
 Risk avoidance, 24  
 Risperidone, 167, 170  
 Rocuronium, 185  
 Rolipram, 293  
 Romifidine, 155  
 Romifidine + propofol, 32  
 R-on-T phenomenon, 232  
 Ropivacaine, 182  
 ROSA26-lac Z reporter mouse strain, 341  
 Rostal (rVLM) and caudal (cVLM)  
   ventrolateral medulla, 334–337  
 Rostral ventrolateral medulla (rVLM), 331  
 R-R intervals, 68, 145  
 RT-1 haplotype, 269  
 R-thiopental, 132  
 Ruminants, 21  
 Russel's viper venom, 314  
 Ryanodine receptor (RyR2), 214, 271  
 RyR2 R176Q mutation, 214
- S**  
 Saffan, 135  
 Salivary secretions, 21  
 Salivation, 150  
 Salt-resistant (Dahl SR), 270  
 Salt sensing, 273  
 Salt-sensitive (Dahl SS), 270  
 Salt-sensitivity, 270  
 Sandhills cranes, 138  
 Sand rats, 324  
 Saphenous arteries, 159, 280  
 Sarafotoxin 6c, 286  
 Saran Wrap(R), 223  
 Sarcolemmal K<sup>+</sup> ATP channels, 138, 151  
 Sarcolemmal L-type Ca<sup>2+</sup> channel proteins, 246  
 Sarcolemmal Na-K-ATPase, 239  
 Sarcomere, 65  
 Sarcomere shortening, 86  
 Sarcoplasmic [Ca<sup>2+</sup>], 157  
 Sarcoplasmic reticular Ca<sup>2+</sup> release process, 137  
 Sarcoplasmic reticulum (SR), 86, 214  
 Sarco (endo) plasmic reticulum Ca<sup>2+</sup> ATPase  
   2a, 271  
 Sarcoplasmic reticulum preparation, 137  
 Scavenger receptor-A, 264  
   expression, 367  
 Scavenger receptor-B1, 379  
 Scavenger receptor class B type1 (SRB1), 317  
 Scintillation counter, 81  
 Sclerotic glomeruli, 280  
 Scn5a, 213, 244  
 Scrambled ODNs, 289  
 Screaming, 34, 37  
 Second extracellular loop of the  $\beta$ 1-adrenergic  
   receptor [ $\beta$ 1-EC(II)], 239  
 Secretion of triglycerides (TG), 346  
 Sector scanning, 72  
 Selective serotonin reuptake inhibitors  
   (SSRIs), 166  
 Selective serotonin uptake inhibitors, 167–169  
 Selegiline, 156  
 Selenium-deficient mice, 209  
 Selenium-vitamin E (Se-E) deficiency, 239  
 Senescent heart failure, 86  
 Senescent mice, 105  
 Senescent rats, 139



- Series elastic element, 65
- Serine  
  protease, 374  
  residues, 370
- Serine-threonine kinase Akt, 245
- Serotonergic inputs, 336
- Serotonergic mechanisms, 343
- Serotonin, 260  
  antagonists, 28  
  receptor-6, 344  
  receptors, 344
- Serotonin (5-HT), 344
- Serotonin (5-hydroxytryptamine; 5-HT)  
  overproduction is, 208
- Serotonin-transforming growth factor- $\beta$  pathway, 206
- Serotonin transporter protein (SERT), 277, 381
- Sertindole, 167, 169
- SERT<sup>-/-</sup> mice, 381
- Sertraline, 167
- Serum-and glucocorticoid-inducible kinase (SGK-1), 282
- Serum-and glucocorticoid-inducible kinase-1 knockout mice (SGK-1<sup>-/-</sup>), 358
- Serum catecholamine concentrations, 137
- Serum creatine kinase levels, 157
- Serum glutamic oxaloacetic transaminase (SGOT), 7
- Serum glutamic pyruvic transaminase (SGPT), 7
- Serum response factor (SRF), 243
- Servoflurane, 29, 31, 36
- Servo-system, 116
- Sesamin, 277
- Sevoflurane, 133, 139–140
- Sevoflurane + N<sub>2</sub>O, 36
- Sex-dependent allele, 233
- Sex hormones, 281
- Sex-related responses, 356–357
- Sexual dimorphism, 343
- Shear stress-induced platelet aggregation, 184
- Shear-wave methods, 85, 105
- Sheep (adult), 4–8, 55–58
- SHHF/MccCr1-Lepr<sup>cp</sup> strain of rats, 241
- Shox2, 214
- Shp2, 243
- SHR/OBKOLCr1-Lepr<sup>cp</sup>, 241
- SHROB strain, 240
- Shunts  
  fraction, 156  
  from LV to left atrium, 237
- Sickle cell disease (SCD) mice, 293
- Signal to noise ratio, 73
- Silver nitrate, 237
- Simple descriptive scale (SDS), 19
- Simpson's rule, 82
- Simvastatin, 212, 286
- Sinclair Farms, 312
- Single sodium channels, 133
- Single uniform elastic tube loaded with a resistive load, 94
- Sinoaortic denervation, 267
- Sinoatrial syncope, 211
- Sinus arrhythmia, 133
- Sinuses of Valsalva, 207
- Sinus node artery, 164
- Sinus node recovery time (SNRT), 69
- Sitafloxacin, 187
- Sleep-promotion, 342
- Slowly activating delayed rectifier K<sup>+</sup> current, 163
- Smad2, 275
- Smad 2/3, 365
- Small artery tone, 357
- Small dense LDL, 308
- SM Cx43<sup>-/-</sup> mice, 322
- Smirk's genetic hypotensive strain, 270
- Smoothelin-A, 288
- Smoothelin-B, 288
- Smoothelin-B knockout (Smtn-B<sup>-/-</sup>) mice, 288
- Smoothelin models, 288
- $\alpha$ -Smooth muscle actin, 212
- $\alpha$ -Smooth muscle actin knockout ( $\alpha$ -SMA), 105
- Smooth muscle cells (SMC), 308
- SM22 promoter, 362
- Snail, 244
- SOD/catalase mimetic (tempol), 283
- Sodium  
  channel blocking agents, 212  
  currents, 133  
  pentobarbital, 23  
  retention, 260
- Sodium chloride, 123
- Sodium nitroprusside, 292
- Somatic analgesia, 150
- Somatic pain, 17
- Sonomicrometry, 81
- Sparfloxacin, 187
- Spatial-temporal artifacts, 76
- Spatiotemporal overexpression of calretxin, 372
- Speckle, 73
- Spectral overlap, 75
- Speed congenic strategies, 259
- Spinal blood flow, 139
- Spinal transection shock, 149
- Spinal trigeminal nucleus (SPV), 333

- Spinal vestibular nucleus (SpVe), 335, 343  
Spinophilin, 285  
Spinophilin-deficient mice (SPL<sup>-/-</sup>), 285  
Spon-1 gene, 267  
Spontaneous autosomal recessive diabetes mutation db, 318  
Spontaneous Ca<sup>2+</sup> release, 139  
Spontaneous involuntary muscle movements, 150  
Spontaneously beating atrial myocardial strip preparations, 147  
Spontaneously beating preparations, 125  
Spontaneously beating Purkinje fibers, 163  
Spontaneously breathing dogs, 142  
Spontaneously hypertensive rat (SHR), 143, 260, 266–269  
Spontaneously hypertensive stroke-prone rats, 259  
Sprague-Dawley (SD), 143  
Sprague-Dawley rats, 176, 220  
SRC-1<sup>-/-</sup> mice, 370  
ssTnI (PBL<sup>-/-</sup>/ssTnI), 370  
Standardbred female horses, 158  
Standing waves, 71  
Staphylococcus aureus  $\alpha$ -toxin, 239  
Starling, E.H., 110, 111  
Static compliance, 101  
Steroid receptor coactivator-1 (SRC-1), 370  
Steroids  
    anesthetic agents, 134–135  
    receptors, 341  
    synthesis, 152  
Sterol esters, 161  
Sterol 27-hydroxylase, 379  
Sterol 27-OH, 317  
Sterols, 161  
S-thiopental, 132  
Stiffness analog, 104  
St. Kitts vervet monkeys, 312  
Strain rates, 76  
Strains, 66, 309  
*Streptococcus pneumoniae*, 210  
*Streptomyces achromogenes*, 308  
Streptomycin, 187  
Streptozotocin (STZ), 238, 308  
Streptozotocin-induced diabetes, 270, 339  
Streptozotocin-induced diabetic rats, 220, 278  
Stress  
    hypertension, 334  
    reaction, 186  
    relaxation, 66  
    response, 147, 184  
    type response, 151  
Striated muscle activator of Rho signaling (STARS), 243  
Stria terminalis, 332  
Stroke-prone renovascular hypertension, 262  
Stroke-prone spontaneously hypertensive rat (SHRSP), 269–270  
Stroke-resistant sub-strains of SHR, 270  
Stroke volume (SV), 132  
    ranges of, 57  
Stroke work, 102  
Stromal cell-derived factor-1 (SDF-1), 292  
*Strongyle* sp., 207  
Strophanthin-K, CaCl<sub>2</sub> and aconitine, 212  
S-T segments, 159  
Student's t-test, 67  
Subarachnoid space, 151  
Subcutaneous edema, 293  
Subendocardium, 158  
Subformal organs (SFOs), 262, 273, 340, 342  
Substance-P, 240  
Subtotally nephrectomized pregnant ewes, 273  
 $\beta$ -Subunit of mink, 212  
 $\alpha$ -Subunits  
    of heterotrimeric G proteins, 245  
    of KvLGT1, 212  
Sub-valvular stenoses, 236  
Succinylcholine chloride, 185  
Sucrose, 272  
Sudden death, 372  
Sufentanil, 149  
Sufentanil/medetomidine, 23  
Sulfonylurea receptors, 151  
Sulphonylurea receptor subunit 2B, 138  
Summing amplifier, 73  
Superoxide dismutase (SOD), 165, 268  
Superoxide dismutase/glutathione peroxidase (GPx) ratio, 292  
Superoxide ion over-production, 358  
Support animals, 122  
Suprachiasmatic nucleus (SCN), 332  
Supraoptic and paraventricular nuclei, 273  
Supraoptic nucleus (SON), 333  
Supravalvular aortic stenosis (SVAS), 204, 376  
Supravalvular mitral stenosis, 204  
Supraventricular driving rate, 136  
Surface potential, 69  
Sweating, 18  
Sweep-scan technique, 75  
Swine models of atherosclerosis, 312  
Swiss albino mice, 158  
Swiss outbred, 280  
Sympathetic hyperactivity, 240  
Sympathetic nerve discharge rhythmicity, 333  
Sympathetic stimulation, 150

- Sympathetic tonic activity, 335  
 Sympatho-excitatory pathway, 333  
 Sympathoexcitatory response, 134  
 Synaptic connections, 338  
 Synthesis of tetrahydrobiopterin (BH4), 292  
 Synthetically tethered ligand domains, 373  
 Synthetic opioids, 149–150  
 Systemic arterial compliance, 132  
 Systemic lupus erythematosus (SLE) mice, 291  
 Systemic oxidative stress, 359  
 Systemic resistance (Rao), ranges of, 56  
 Systemic vascular resistance, 132  
 Systolic and diastolic properties, 67  
 Systolic dysfunction, 206  
 Systolic hypertension, 102  
 Systolic velocities, 76, 105
- T**
- Tachycardia, 21, 262  
 Taenia crassiceps, 240  
 Tafazzin gene, 233  
 Talin-1, 293  
 T and B cells, 380  
 Targeted gene knock-in models, 356  
 Tau, ( $\tau$ ), 70  
 Taurine levels, 157  
 T-box family transcription factor gene, 244  
 T-box transcription factor, 356  
 T-box transcription factor gene, 377  
 TBX20, 244  
 Tearing, 24  
 Technitium-99m, 82  
 Teeth grinding, 24  
 Teflon felt, 207, 237  
 Telazol®, 29, 36, 152  
 Telazol (tiletamine/zolazepam), 32  
 Telazol+ etomidate, 32  
 Telazol+ medetomidine, 32  
 Telazol+ xylazine, 32  
 Telemetry, 69  
 Telmisartan, 271  
 Telomerase activity, 360  
 Temperature, 65  
 Tempol, 275  
 Tenidap, 183  
 Tenoxicam, 183  
 Tension, 66  
 Teratogenic effects, 183  
 Terminal lever-pressing rates, 269  
 Testosterone, 344  
 Tetracyclines, 187  
 Tetradecylthioacetic acid (TTA), 261  
 Tetraloy of Fallot, 203  
 Tetrapods, 339  
 TF (sTF)-induced swelling, 374  
 TGF- $\beta$  1, 339  
 TGF-beta-activated CD8<sup>+</sup> T cells, 127  
 TGH rabbits, 314  
 TG9 mouse, 245  
 TG1306/1R mice, 284  
 Thalamic neurons, 342  
 Thalamocortical system, 150  
 Thalamus, 332, 341  
 The apoE lipoprotein knockout, 318–319  
 Thebesian venous drainage, 110  
 The  $dP/dt_{max}$ -end-diastolic volume relation, 103  
 The low-density lipoprotein receptor knockout, 320–321  
 Thermoregulation, 342  
 Thermoregulatory responses, 3  
 Thiamyl sodium, 40  
 Thiazide-sensitive mechanisms, 366  
 Thiobarbiturates, 131  
 Thiobarbituric acid-reactive substances (TBARS), 336  
 Thiol oxidative stress, 322  
 Thiopental, 32, 132  
 Thiopropyluracil, 315  
 Thioredoxin, 274  
 Three-dimensional movement, 80  
 Three-dimensional reconstruction algorithms, 81  
 Three-element windkessel, 100  
 Three-element windkessel model, 93  
 Thrombin, 373  
 Thrombin-antithrombin complex (TAT), 233  
 Thrombocytopenia, 210  
 Thromboembolism, 233  
 Thrombopoiesis, 378  
 Thromboses, 316  
 Thrombosis, 309  
 Thrombospondin-1, 377  
 Thrombospondin-1<sup>-/-</sup>, 377  
 Thromboxane receptor (Tp), 380  
 Thromboxane-receptor-deficient mice (TP<sup>-/-</sup>), 279  
 Thymosin  $\beta$ -4 (T- $\beta$ -4), 381  
 Thymulin, 293  
 Thyroid hormone, 127  
 TIE2-lacZ mice, 363  
 Tiletamine, 151–152  
 Tiletamine + zolazepam (Telazol®, Zoletil®), 29, 181–182  
 Time-dependent outward K<sup>+</sup> current, 164  
 Time-varying elastance, 84–85  
 Time-varying elastance of LV, 102  
 TIMP-3<sup>-/-</sup> mice, 374  
 Tissue angiotensin-II production, 261

- Tissue characterization, 85, 105  
 Tissue Doppler displacement method, 104  
 Tissue Doppler imaging (TDI), 74–77, 104–105  
 Tissue high-energy phosphate, 163  
 Tissue inhibitor of metalloprotease-3 (TIMP-3), 374  
 Tissue inhibitor of metalloproteinase-2 (TIMP-2), 277  
 Tissue-type plasminogen activator (t-PA), 321  
 TLR-4<sup>-/-</sup>mice, 368  
 TNF- $\alpha$ , 210, 339  
 TNF- $\alpha$ <sup>-/-</sup>mice, 210, 225, 365  
 TNF- $\alpha$ -1R<sup>-/-</sup>, 320  
 Tolfenamic acid, 183  
 Toll-like receptors (TLR), 368  
 Toll-like receptors 2 and 4, 237  
 Tonicity, 333  
 Torsades de pointes, 161, 163, 211  
 Torsion, 77  
 Total antioxidant activity, 206  
 Total antioxidant capacity, 268  
 Total body O<sub>2</sub> consumption, 137  
 Total canine bilirubin, 3  
 Total cholesterol (TC), 7  
 Total heart function, 117  
 Total magnesium efflux, 151  
 Total peripheral resistance, 100, 261  
 Total protein (TP), 7  
 Toxicosis and mineral-deficient models of cardiomyopathy, 239  
 t-PA (t-PA<sup>-/-</sup>), 321  
 Tp<sup>-/-</sup>mice, 380  
 Tranquilizers, 22  
 Transcriptional coactivator, 370  
 Transdifferentiation, 127  
 Transducer  
   frequency, 80  
   operating frequency, 73  
   sweep velocity, 76  
 Trans fatty acids, 311  
 Transforming growth factor- $\beta$  (TGF- $\beta$ ), 212  
 Transgenic cardiac overexpression of human P2X4R, 374  
 Transgenic CMY-mOVA mice, 363  
 Transgenic Cre/lox mice, 369  
 Transgenic mice, 73  
   containing the human A20 gene, 369–370  
   expressing PPAR- $\gamma$ -1, 366  
   expressing viral interleukin (vIL-10), 363  
   overexpressing canine junction, 371  
   overexpressing cardiac troponin-I (TnI), 370  
   ubiquitously expressing LacZ (LacZ-mice), 323  
 Transgenic models, of pulmonary hypertension, 294  
 Transgenic mouse models, 322–323  
 Transgenic pigs  
   carrying an endogenous eNOS gene driven by a Tie-2 promoter, 361  
   co-express hCD59 and HT, 363  
 Transgenic rabbits, 369, 372, 374  
   models, 314  
   overexpressing human matrix metalloproteinase-12 (hMMP-12-TG), 374  
   overexpressing PLN, 372  
 Transgenic rat models, 317  
 Transient hyperglycemia, 144  
 Transient ischemic attacks, 225  
 Transient method, 105  
 Transient outward K<sup>+</sup> current, 165  
 Transient receptor potential vanilloid (TRPV)  
   family of cation channels, 333  
 Transient receptor potential vanilloid type-1 (TRPV1), 277  
 Transient response, of tissue, 85  
 Transmitral Doppler E and A-waves, 78  
 Transmural cryoinjury lesion, 224  
 Transplanted organs, 323  
 Treppe phenomenon, 109  
 Triadin-1, 371  
 Trichloroethylene, 140–141  
 Tricuspid atresia, 204  
 Tricuspid regurgitation (TR), 206  
 Tricyclic antidepressants, 21, 167, 212  
 Triflupromazine, 163  
 Triglycerides (TG), 7, 308  
 Trimetazidine, 220  
 Trimipramine, 167  
 Triple adrenoceptor knockouts ( $\beta$ -1/ $\beta$ -2/ $\beta$ -3 AR<sup>-/-</sup>), 360  
 $\beta$ -Tropomyosin, 245  
 Troponin, 370  
 Troponin C, 231  
 Troponin T (TnT), 370  
 Troponin T binding region, 241  
 TRP cation channel, TRPC6, 245  
 TRPV-1<sup>-/-</sup>mice, 381  
 Truncated cardiac troponin T, 241  
 Trypsin, 373  
 Tryptase, 373  
 Tryptophan, 159  
 Tsukuba hypertensive mouse, 290  
 T tubules, 371  
 Tubule vacuolization, 279  
 Tubulointerstitial angio-II positive cells, 272  
 Tubulointerstitial infiltration, 280  
 Tubulointerstitial inflammation, 263

- Tumor necrosis factor (TNF), 7  
 Tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), 245  
 Tumor necrosis factor receptor-1 fusion protein (TNFR1-IgG<sup>-/-</sup>) transgenic mice, 365  
 Two-dimensional ultrasound, 71  
 Two elastic tubes  
   in parallel (T-tube model), 94  
   in series, 94  
 Two-element windkessel, 93  
 Tygon(R) tubing, 223  
 Type-1 (insulin-dependent), 307  
 Type-2 (non-insulin-dependent) diabetes, 307  
 Tyramine pressure response, 171  
 Tyrosine, 159  
 Tyrosine hydroxylase (TH), 336, 339  
 Tyrosine hydroxylase (TH) and phenylethanolamine N-methyltransferase (PNMT), 346  
 Tyrosine hydroxylase-immunoreactive (TH-ir) neurons, 336, 346–348
- U**  
 Ubiquitin, 365  
 Ubiquitin proteasome, 242  
 Ulcerated lesions, 316  
 Ultrasonic reflectoscope, 71  
 Ultrasound, 70  
 Ultrastructural lesions, 239  
 Umbilical blood flow, 144  
 Umbilical tape, 222  
 Umbilical vein glucose levels, 144  
 Unconditional fear in rats, 340  
 Uniform tube loaded with a complex load, 94  
 Unilateral nephrectomy, 276  
 Unilateral nephrectomy plus DOCA-salt, 276  
 Universal transgenic reporter mouse strain, 355  
 Upper airway resistance, 141  
 Urea nitrogen, 3  
 Urethane, 134  
 Urinary excretion, 283  
 Urinary Na<sup>+</sup> excretion, 279  
 Urinary nitrogen, fecal nitrogen, 4  
 Urinary retention, 22  
 Urine output, 4, 24  
 Urotensin-II (UII), 340, 347  
   binding sites, 347  
   receptor mRNA, 347  
 Uteroplacental insufficiency, 282  
 Uteroplacental perfusion, 281
- V**  
 Vagal afferent terminals, 337  
 Vagal tone, 21  
 Vagolytic effects, 185  
 Vagotomized, 154  
 Valpha14Jalpha8 T-cell receptor transgenic mice, 321  
 Valsartan, 283  
 Valvular insufficiency, 236  
 Valvular stenoses or insufficiencies, 237  
 Valvuloseptal hypercellularity, 140  
 Vancomycin, 187  
 Vanilloid type-1 receptors (TRPV-1), 381  
 VAS, 34  
 Vasa vasorum, 310  
 Vascular aging, 273  
 Vascular cell adhesion molecule-1 (VCAM-1), 288, 308  
 Vascular cell adhesion molecule-1 (VCAM-1)<sup>-/-</sup>, 321  
 Vascular diathesis, 272  
 Vascular endothelial growth factor (VEGF), 360  
   protein, 143  
   transgenic mouse, 378  
 Vascular endothelial growth factor receptor (VEGFR), 292  
 Vascular endothelium, 355  
 Vascular function, 93–105  
 Vascular mechanical behavior, 99–101  
 Vascular myogenic tone, 379  
 Vascular rarefaction, 236  
 Vascular remodeling, 273, 358  
 Vascular smooth muscle (VSM), 264  
 Vascular smooth muscle cells (VSMCs), 285, 357  
 Vascular stiffness, 261  
 Vasculopathy, 316  
 Vasodepressor activity, 150  
 Vasomotion, 134  
 Vasopressin (AVP), 265, 337, 345  
 Vasopressin deficiency, 269  
 Vasopressin-dependent vascular tone, 134  
 VDR<sup>-/-</sup> mice, 380  
 Vector  
   cardiogram, 168  
   loop, 69  
 Vecuronium, 185  
 VEGF(121), 143  
 VEGF(165), 143  
 VEGF HIP-alpha DNA response element, 143  
 VEGF-mediated phosphorylation of Akt and eNOS, 369  
 Velocity, 65

- Velocity of circumferential fiber shortening, 132  
 Vena caval pressures, 142  
 Venlafaxin, 167  
 Venous anomalies, 203  
 Venous  $O_2$ , 133  
 Venous  $pCO_2$ , 175  
 Ventilator-induced lung injury, 360  
 Ventral roots in cats, 332  
 Ventricular arrhythmias, 136, 235  
 Ventricular/arterial coupling dynamics, 93–105  
 Ventricular automaticity, 136, 155  
 Ventricular bigeminy, 232  
 Ventricular cardiomyocytes, 133  
 Ventricular chamber, 86  
 Ventricular compliance, 86  
 Ventricular conduction, 136  
 Ventricular diastolic properties, 68  
 Ventricular dilation, 219  
 Ventricular effective refractory period, 165  
 Ventricular elasticity, 68  
 Ventricular escape, 136  
 Ventricular excitation, 3  
 Ventricular fibrillation, 137, 211, 212, 214  
 Ventricular fibrillation threshold, 146  
 Ventricular functional refractory period, 136  
 Ventricular hypertrophy, 271, 356  
 Ventricular multiple response threshold, 160  
 Ventricular myocytes, 133  
 Ventricular septal defect (VSD), 203  
 Ventricular strips, 65  
 Ventricular tachyarrhythmias, 136, 140  
 Ventricular trabeculae, 139  
 Ventricular/vascular coupling, 101–104  
 Ventricular volumes, 80  
 Ventrobasal complex, 342  
 Veratridine, 334  
 Vernier caliper, 222  
 Very low-density lipoprotein (VLDL), 308  
 Vestibulo-cardiovascular pathway, in brain stem, 332  
 Vestigial pulmonary artery, 204  
 Vevo 660 VisualSonics, 79  
 Vibro-acoustography, 105  
 Vinculin, 244  
 Visceral analgesia, 150  
 Visceral pain, 17  
 Viscoelastic properties, 86  
 Visual analogue scale (VAS), 19  
 VisualSonics biomicroscope, 78  
 Vitamin D  
   deficiency, 380  
   receptor models, 287  
 Vitamin D receptor (VDR), 380  
 Vitamin D receptor knockout (VDR<sup>-/-</sup>) mice, 287  
 VIVID 7, 78  
 Vocalization, 18, 34  
 Voigt model, 96  
 Volatile anesthetic agents, 135  
 Voltage-clamped canine ventricular myocytes, 170  
 Voltage-dependent  $Ca^{2+}$  channels (VDCCs), 338  
 Voltage-gated  $Na^+$  currents, 244  
 Voltage-regulated potassium channel KCNQ1, 244  
 Volume axis intercept ( $V_0$ ), 67  
 Volume distensibility ( $E_v$ ), 96–97  
 Volume elasticity, 66  
 Volume overload, 236, 237  
 Volume-regulated anion channels, 273  
 Volume-sensitive  $Cl^-$  current, 168  
 $VO_{2max}$ , 158  
 Von Bezold-Jarisch reflex, 333  
 Von Willebrand factor, 206  
 VS40, 78  
 VSM-derived hypertensive mouse, 291  
 V3 venules, 133  
 VWF-lacZ mice, 363
- W**  
 Walker Hounds, 178  
 Wall motion score index (WMSI), 79  
 Wall stiffness, 94  
 Wall-thickening, 80  
 Washed red blood cell, addition to the perfusate, 122  
 Washed red blood cells, 113  
 Watanabe heritable hyperlipidemic rabbits, 313  
 Water consumption, 4, 24  
 Wavelet transform, 76  
 Wave reflections, 95  
 Weanling rabbits, 237  
 Weight loss, 37  
 Wenckebach, 69  
 Whining, 34  
 Whole blood, 113  
 Whole mount confocal microscopy, 141  
 Wiggers, Carl., 109  
 Wild pigs, 41  
 Wild-type mice, 105  
 Windkessel, 93  
 Wistar-Kyoto, 143  
 Wistar-Kyoto (WKY) rat, 266

Wistar rats, 158, 176, 345

WKY rats, 133

Wnt3a, 362

Wnt7a, 362

Wooly hair, 234

Working heart-lung preparation, 115

Wp/Wt, 102

## **X**

Xanthomas, 320

Xanthone derivative, 225

X chromosomal microsatellites, 233

X chromosome, 266

Xenotransplantation, 362–364

Xenotransplants, 126

Xylazine, 30, 172

Xylazine + morphine, 181

Xylazine + propofol + sevoflurane, 36

## **Y**

Yang, A., 359

Y chromosome, 266

Yin, F., 359,

Yohimbine toxicity, 171

Yowling, 37

## **Z**

ZDF/Crl-Lepr<sup>fa</sup>, 241

Zispraside, 167

Zolazepam, 151

Zucker diabetic fatty rat (ZDF), 315